Stable formulations containing 225-actinium-labeled complexes and their preparation methods
By using sodium acetate and ethanol in the formulation of actinium-225-labeled radionuclide complexes, the problem of poor stability of actinium-225-labeled drugs was solved, and high stability and high purity of radionuclide complexes were achieved at room temperature for 72 hours, simplifying the preparation process.
Patent Information
- Application Number
- CN202580026349.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-04-15
- Filing Date
- 2025-04-15
- Publication Date
- 2026-11-10
AI Technical Summary
In the existing technology, actinium-225 labeled radionuclide complexes have poor stability during production, storage and transportation, resulting in short shelf life, low purity, and difficulty in ensuring the long-term stability and high purity of radiopharmaceuticals.
A formulation containing sodium acetate and ethanol is used as a stabilizer and buffer for actinium-225-labeled radionuclide complexes to form a pharmaceutical composition containing a targeting portion of prostate-specific membrane antigen (PSMA) or αvβ3 integrin, thereby improving the stability and purity of the radionuclide complex.
This method achieves high stability and high purity of radionuclide complexes at room temperature for at least 72 hours, simplifies the preparation process, reduces the number of components, avoids complex mixing and purification steps, and ensures long-term storage and transportation of the drug.
Smart Images

Figure SMS_1 
Figure SMS_10 
Figure SMS_22
Abstract
Description
[0001] This invention relates to the field of radiopharmaceutical formulations, and more specifically to formulations that ensure the stability of radionuclide complexes and methods for preparing such formulations.
[0002] Radiopharmaceuticals are drugs containing radioactive isotopes (radionuclear substances). Radiopharmaceuticals can be used to treat a variety of conditions, including cancer, blood disorders, and hyperthyroidism. In radionuclide therapy for cancer, molecules labeled with radionuclear substances are used to deliver toxic levels of radiation to the disease site. Thus, the molecule is used to "target" the disease site, such as specific cancer cells. Therefore, radionuclide complexes combine the specificity of cancer cell targeting with the known antitumor effects of ionizing radiation. This allows targeting not only the primary tumor site but also its metastases. The choice of molecules carrying radiation to the tumor is usually determined by their selectivity and affinity for the tumor's target structures, such as antigens or receptors. Even if a target structure is not selective for a particular cancer, overexpressed target structures are meaningful because they allow for the delivery of radionuclide complexes at high concentrations to those (overexpressed) target cells after systemic administration, while leaving other cells (without expression or with only minimal expression) largely unaffected.
[0003] Radionuclides are typically linked to their target sites via chelating moieties. This allows them to form strong complexes with the metal ions of the radionuclides. The radioactive decay of radionuclides can cause significant damage to cancer cells by releasing high-energy electrons, positrons, alpha particles, and gamma rays at the target site.
[0004] However, radioactive decay of radionuclides continues, including during the production and storage of radionuclide complexes. The high energy released during radioactive decay can induce the breaking of chemical bonds in radionuclide complexes, leading to partial destruction of the drug due to its radioactivity. Radiation degradation of the target portion of radionuclide complexes may result in reduced specificity, leading to decreased potency and / or increased undesirable side effects.
[0005] Actinide-225 225 Ac is one of the most promising radionuclides for targeted alpha therapy, with a half-life of 9.92 days and a decay chain that releases four high-energy alpha particles.
[0006] The most common radiolabeling strategies described in the literature for labeling different precursor compounds with Ac-225 typically involve using TRIS buffer (tris(hydroxymethyl)aminomethane) at pH 9 or ascorbate buffer at pH 4–6, followed by heating at 90–95°C for 15–45 minutes. Labeling efficiencies of 90%–95% have been reported (Hooljman EL et al., Development of […]).225 Ac]-PSMA-I&T for Targeted Alpha Therapy According to GMPGuidelines for Treatment of mCRPC. Pharmaceutics 2021. 13, 715; Morgenstern A et al. Bismuth-213 and Actinium-225 – Generator Performance and EvolvingTherapeutic Applications of Two Generator-Derived Alpha-EmittingRadioisotopes. Current Radiopharmaceuticals, 2012, 5, 221-227; Pretze M et alAc-EAZY! Towards GMP-Compliant Module Syntheses of 225 Ac-Labeled Peptides for Clinical Application. Pharmaceuticals 2021, 14, 652. Even under optimized conditions, formulations containing this radionuclide complex still contain up to 2% unconjugated Ac-225 (Hooljman et al., 2021, supra). The indicated amount of unconjugated Ac-225 either requires further purification of the drug product (Hooljman et al., 2021, supra; Pretze et al., 2021). Another possibility is to add a weak chelating agent, such as DTPA or EDTA, to the formulation to bind the radiotoxic unconjugated Ac-225 and rapidly eliminate it from the organism (Hooljman et al., 2021, supra; Pretze et al., 2021). However, it should be noted that the weak chelating agents DTPA and EDTA do not provide sufficient strength to complex Ac-225, and can only guarantee the undesirable accumulation of Ac-225 in healthy tissues with low reliability (Deal K. A. et al., Improved in Vivo Stability of Actinium-225 Macrocyclic Complexes. J. Med. Chem. 1999. 42, 2988-2992). Therefore, no method has been described in the current literature that can guarantee a radiochemical yield ≥99% […]. 225 Labeling conditions for Ac-labeled substances.
[0007] Following radiolabeling of precursor compounds, the stability of radiopharmaceuticals is typically limited to a few hours or days. This leads to various challenges in the production, storage, and transportation of radiopharmaceuticals. Consequently, only a small time window is available after production for the application of radiopharmaceuticals.
[0008] To mitigate this problem, antioxidants such as gentianic acid, ethanol, ascorbic acid, and methionine are typically added to formulations containing radionuclide complexes. However, this is particularly true for formulations using... 177 Lu-labeled peptides, such as DOTATOC (edotreotide) and DOTATATE (oxodotreotide), typically require complex mixtures of antioxidants or the addition of these antioxidants at specific time points to achieve the desired effect over an acceptable period of time. For example, Maus et al. reported […]. 177 Lu-DOTATATE was radiolabeled and purified, followed by the addition of ascorbic acid (Stephan Maus et al., Aspects on radiolabeling of...). 177 Lu-DOTA-TATE: After C18purification re-addition of ascorbic acid is required to maintain radiochemical purity, International Journal of Diagnostic Imaging, 2014, Vol.1, No. 1).
[0009] US Patent 10,756,278B2 requires the use of a complex mixture of gentianic acid, ascorbic acid, and EDTA after radiolabeling to achieve 95% of the desired resistance to radiodegradation 72 hours after synthesis. De Blois et al. and Breeman et al. even suggested adding a mixture of 50 mM ascorbic acid, 10% (v / v) ethanol, and 50 mM L-methionine (Erik de Blois et al., Effectiveness of Quenchers to Reduce Radiolysis of 111 In-or 177Lu-labelled Methionine-Containing Regulatory Peptides. MaintainingRadiochemical Purity as Measured by HPLC. Curr Top Med Chem. 2012;12(23):2677-85; Wouter AP Breeman; Practical Aspects of labeling DTPA- and DOTA-Peptides 90 Y, 111 In, 177 Lu, and 68 Ga for Peptide-Receptor Scintigraphy and Peptide-Receptor Radionuclide Therapy in Preclinical and Clinical Applications; The University of New Mexico Health Sciences Center, VOLUME 16, LESSON 5: 11 / 16 / 2012). According to these reports, for... 177 The Lu-labeled peptide, stabilizer, or either the second or third stabilizing component, is added to the acetate or HEPES buffer only after radiolabeling is complete.
[0010] The intensity of radiolysis also depends particularly on the amount of chemical precursors (peptides) used, the concentration of radioactivity, and the type and concentration of antioxidants. In addition to radiolysis stability, pH must be carefully considered for radiopharmaceuticals administered externally. Therefore, the composition of multi-component formulations for stabilizing therapeutic radiopharmaceuticals is a complex issue. Alpha emitters are particularly prone to causing radiation-induced damage to radiopharmaceuticals. Alpha radiation has an energy of approximately 4 to 5 MeV, which is orders of magnitude higher than that of beta radiation. Therefore, alpha radiation not only has a significantly higher energy intensity but also releases this energy within a smaller radius from the decay source due to its high interaction with matter. The only approved alpha-emitting radiopharmaceutical to date […]. 223 Ra]RaCl2 is chemically inert and, as a pharmaceutical preparation containing dissolved salts, is unaffected by radiation decomposition.
[0011] In contrast, antibody or peptide conjugates of DOTA, DOTAGA, or Macropa with Ac-225, Pb-212, or other α-emitters are susceptible to radiation degradation, and the reported shelf life of these drugs is limited to only a few hours (Hooijman et al., Development of […]). 225 Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMPGuidelines for Treatment of mCRPC. Pharmaceutics 2021, 13, 715).
[0012] The low stability of Ac-225 radiopharmaceuticals results in a short shelf life, which is a major obstacle to centralized production. This is not only due to insufficient radioanalysis of Ac-225-labeled compounds, but also because of the strong radiodecomposition properties of alpha emitters. It has been reported that the purity of Ac-225 radiopharmaceuticals is currently only >90% for many human applications (Pretze et al., Ac-EAZY! Towards GMP-Compliant Module Syntheses of 225 Ac-Labeled Peptides for Clinical Application. Pharmaceuticals 2021, 14, 652). This purity is significantly lower than the current quality of other therapeutic radiopharmaceuticals, for example... 177 Lu-DOTATOC 177 Lu-DOTATATE (Lutathera) or 177 The quality of Lu-PSMA-617.
[0013] However, in the current literature, there is no description of […]. 225 Formulations of Ac-labeled compounds ensure stability for at least 72 hours, purity ≥94%, and are free and uncomplexed. 225 Ac 3+ ≤1%.
[0014] US Patent Application US2023 / 0144360A1 describes a liquid radiopharmaceutical composition targeting the somatostatin receptor, comprising (a) 225 Ac-DOTA-TATE or a pharmaceutically acceptable salt thereof, (b) sodium ascorbate at a concentration of 40 mM to 250 mM, (c) diethylenetriaminepentaacetic acid (DTPA), and (d) a salt solution as an aqueous carrier. According to US2023 / 0144360A1, the radiopharmaceutical composition disclosed therein retains its properties after 120 hours at 20°C to 25°C.225 Ac-Dotatate form retains at least 90% 225 Ac content.
[0015] In view of the above, the object of the present invention is to overcome the above-mentioned disadvantages and to provide a complex containing a radionuclide, particularly a radioactive nuclide complex. 225 A pharmaceutical composition of Ac-labeled complexes that ensures increased purity and stability of the radionuclide complex over a longer period. Another object of the present invention is to provide a rapid and simple... 225 Ac radiolabeling method and method for preparing pharmaceutical compositions, the method providing a radiodegradable formulation containing as few components as possible.
[0016] The objective is achieved by the subject matter set forth below and in the appended claims.
[0017] Although the invention has been described in detail below, it should be understood that the invention is not limited to the specific methods, schemes, and reagents described herein, as these can be varied. It should also be understood that the terminology used herein is not intended to limit the scope of the invention, which is limited only by the appended claims. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains.
[0018] The elements of the invention will be described below. These elements are listed by specific embodiments; however, it should be understood that they can be combined in any manner and in any number to produce other embodiments. The various described examples and preferred embodiments should not be construed as limiting the invention to the explicitly described embodiments. This description should be understood to support and cover embodiments that combine the explicitly described embodiments with any number of the disclosed and / or preferred elements. Furthermore, unless the context otherwise requires, any permutation and combination of all described elements in this application should be considered as disclosed by the description in this application.
[0019] Throughout this specification and the appended claims, unless the context otherwise requires, the terms “comprising” and “including” shall be understood to imply the inclusion of stated members, integers, or steps, but not to exclude any other unstated members, integers, or steps. The term “consisting of” is a specific embodiment of the term “comprising”, in which any other unstated members, integers, or steps are excluded. In the context of this invention, the term “comprising” encompasses the term “consisting of”. Therefore, the term “comprising” covers both “including” and “consisting of”, for example, a composition “comprising” X may consist of only X or may contain additional elements, such as X+Y.
[0020] Unless otherwise stated herein or clearly contradicted by the context, the absence of quantifiers preceding elements and similar references used in the context of describing the invention (especially in the context of the claims) should be interpreted as encompassing both singular and plural forms. The descriptions of numerical ranges herein are intended only as a concise way of referring individually to each individual value falling within that range. Unless otherwise stated herein, each individual value is incorporated into this specification as if it were described individually herein. No language in this specification should be construed as indicating that any unclaimed element is necessary for the implementation of the invention.
[0021] The term "substantially" does not exclude "completely," for example, a composition that is "substantially free" of Y may be completely free of Y. The term "substantially" may be omitted from the definition of this invention when necessary.
[0022] The term “about” for the numerical value x means x ± 20%, preferably x ± 10%, more preferably x ± 5%, even more preferably x ± 2%, and even more preferably x ± 1%.
[0023] Pharmaceutical Composition
[0024] The first aspect of the present invention provides a pharmaceutical composition comprising:
[0025] (a) A radiolabeled complex containing (i) 225 Ac(actinium-225) radionuclide, and (ii) a targeting portion that targets prostate-specific membrane antigen (PSMA) or αvβ3 integrin, said targeting portion being covalently linked to the chelating portion; and
[0026] (b) Stabilizers that resist radiation degradation.
[0027] The stabilizer mentioned above contains sodium acetate (NaOAc) and ethanol (EtOH).
[0028] The inventors were surprised to discover that this formulation of the radionuclide complex ensured improved radiochemical purity and stability when stored at room temperature (RT) for extended periods, particularly at least 72 hours. This extended stability of 72 hours with consistently high quality allows for centralized production and subsequent distribution of the drug to treatment centers.
[0029] Interestingly, the increased stability / shelf life compared to existing formulations for radionuclide complexes can be achieved with formulations containing fewer components. In particular, sodium acetate (NaOAc), used as a formulation stabilizer, also acts as a buffer for radiolabeling, resulting in high radiolabeling yields and thus avoiding complex mixtures. Furthermore, sodium acetate (NaOAc), used as a formulation stabilizer, can act as a pH adjuster / buffer (especially within a pH range acceptable for non-enteric injection, such as pH 6 to pH 8), further avoiding complex mixtures. Additionally, the purification of the labeled end product and the addition of a weak complexing agent to the formulation can be omitted.
[0030] Radiolabeled complexes
[0031] The radiolabeled complex of the pharmaceutical composition according to the invention comprises (i) 225 Ac (actinium-225) radionuclide, and (ii) a targeting portion of prostate-specific membrane antigen (PSMA) or αvβ3 integrin, wherein the targeting portion is covalently linked to the chelating portion.
[0032] Chelated portion
[0033] In radiolabeled complexes, radioactive nuclide metal ions 225 Ac typically forms non-covalent bonds with functional groups of the chelating moiety, such as amino or carboxylic acid functional groups. Typically, the chelating moiety has at least two such complexing functional groups to enable the formation of chelate complexes.
[0034] As used herein, the term "chelating moiety" (also known as "chelating agent") refers to a polydentate (multiple-bonded) ligand capable of forming two or more separate coordinate bonds ("coordinating") with a central (metal) ion, particularly a radioactive nuclide metal ion. Specifically, such a molecule, or a molecule sharing an electron pair, may also be called a "Lewis base." The central (metal) ion is typically coordinated to the chelating moiety by two or more electron pairs. The terms "binderate chelating moiety," "tridentate chelating moiety," and "tetradentate chelating moiety" are known in the art and refer to chelating moieties having two, three, and four electron pairs, respectively, which readily donate to the metal ion coordinated to the chelating moiety simultaneously. Typically, the electron pairs of the chelating moiety form coordinate bonds with a single central (metal) ion; however, in some instances, the chelating moiety can form coordinate bonds with more than one metal ion, where various binding modes are possible.
[0035] The terms “coordination” and “coordination” refer to an interaction in which a multi-electron-pair donor coordinates (is “coordinated”) to a central (metal) ion, that is, shares two or more unshared electron pairs with the central (metal) ion.
[0036] The chelating agent or chelating moiety is preferably a macrocyclic bifunctional chelating agent having a metal chelating group at one end and a reactive functional group at the other end capable of binding with other moieties, such as peptides. Preferably, the chelating moiety is selected such that it forms a square bipyramidal complex for chelating radionuclides. In another embodiment, the chelating moiety does not form a planar or square planar complex.
[0037] The chelating moiety can be selected based on its ability to coordinate with the desired central (metal) ion, particularly actinium-225. Therefore, any chelating moiety capable of complexing... 225 All chelated portions of Ac can be applied to the radiolabeled complexes according to the present invention.
[0038] Therefore, not limited thereto, the chelate moiety may be selected, for example, from 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and its derivatives, 2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane-1-yl)-glutaric acid (DOTAGA) and its derivatives (e.g., DOTAGA-Anhydrid (DOTAGA-anhydride)), N,N'-bis[(6-carboxy-2-pyridyl)methyl]-4,13-diaza-18-crown-6 (H2-Macropa) and its derivatives (H2-Macropa-NCS, H2-BZ-Macropa, H2-BZ2-Macropa, H2-BZ-Macropa-NCS), crown ethers and their derivatives, and H4py4pa.
[0039] Accordingly, the chelate portion can be characterized by one of the following equations (1a) to (1k):
[0040]
[0041] DOTA (1a) DOTAGA (1b)
[0042]
[0043] DOTAGA-Acid Anhydride (1c) Macropa (1d)
[0044]
[0045] Macropa-NH2 (1e) Macropa-NCS (1f)
[0046]
[0047] H2-BZ-Macropa (1g) H2-BZ2-Macropa (1h)
[0048]
[0049] H2-BZ-Macropa-NSC (1i) Crown ether (1j)
[0050]
[0051] H4py4pa (1k)
[0052] Preferably, the chelating moiety is selected from DOTA, DOTAGA, Macropa, and crown ethers, or derivatives thereof. Particularly preferably, the chelating moiety is DOTA (which can be characterized by formula (1a)) or a derivative thereof. DOTA can effectively bind with… 225 Ac forms complexes for imaging and therapeutic purposes, i.e., as diagnostic agents.
[0053] Includes (i) radionuclides 225 The radiolabeled complexes of Ac and (ii) targeting PSMA or αvβ3 connected to the chelate portion are preferably formed in the radiolabeling method described below.
[0054] Targeted portion
[0055] As used herein, the term "targeting fraction" refers to a molecule capable of (specifically) binding to a "target," such as a target cell (e.g., a cancer cell). Specifically, the "target" can be a molecule located on the cell surface of the target cell (e.g., a cancer cell). Such a surface molecule bound by the targeting fraction can be, for example, a receptor located on the cell surface. Specifically, the surface molecule is specific to or overexpressed by the target cell (e.g., a cellular "marker"). The targeting fraction can bind, for example, a disease (e.g., cancer) marker (which is expressed / localized on the surface of cells involved in the disease, such as cancer cells). Thus, the targeting fraction can specifically direct the radionuclide to cells involved in the disease, such as cancer cells. Therefore, the targeting fraction is typically selected based on the disease to be treated or diagnosed. In the context of a disease, such as cancer, cells targeted with a radiolabeled complex, such as cancer cells, typically express (or overexpress) specific molecules that can serve as "targets" (surface molecules). The targeting moiety is typically selected such that it binds to the "target" (surface molecule, and consequently, target cell, such as cancer cell). The binding of the targeting moiety to the surface molecule can be reversible or irreversible. Preferably, the targeting moiety is selected from peptides, peptide mimics, antibodies, antibody fragments, and antibody mimics. In some embodiments, the targeting moiety is a peptide or polypeptide, or a modified peptide or polypeptide.
[0056] In the radiolabeled complex of the pharmaceutical composition according to the invention, the targeting portion targets PSMA or αvβ3 integrin and is therefore able to bind to PSMA or αvβ3 integrin.
[0057] PSMA-targeting compounds
[0058] In some embodiments, the radiolabeled complex of the pharmaceutical composition according to the invention comprises a targeting portion that targets PSMA.
[0059] Human prostate-specific membrane antigen (PSMA) (also known as glutamate carboxypeptidase II (GCPII), folate hydrolase 1, folypoly-gamma-glutamate carboxypeptidase (FGCP), and N-acetylated-α-linked acidic dipeptidase I (NAALADase I)) is a type II transmembrane zinc metallopeptide. As used herein, the term "human prostate-specific membrane antigen" or "PSMA" preferably refers to the protein encoded by the human FOLH1 gene. More preferably, the term refers to the protein characterized as under UniProt accession number Q04609 (entry version 186, last modified May 10, 2017), or its functional variants, isotypes, fragments, or (post-translational or otherwise modified) derivatives.
[0060] Prostate-specific membrane antigen (PSMA) is overexpressed in most prostate cancer cases (Silver, DA; Pellicer, I.; Fair, WR; Heston, WD; Cordon-Cardo, C. Prostate-specific membrane antigen expression in normal and malignant human tissues. ClinCancer Res 1997, 3, (1), 81-5; Cunha, AC; Weigle, B.; Kiessling, A.; Bachmann, M.; Rieber, EP. Tissue-specificity of prostate specific antigens: comparative analysis of transcript levels in prostate and non-prostatic tissues. Cancer Lett 2006, 236, (2), 229-38).Therefore, it has become a promising target for nuclear imaging and radionuclide therapy in metastatic castration-resistant prostate cancer (mCRPC) (Bouchelouche, K.; Choyke, PL Prostate-specific membrane antigen positron emission tomography in prostate cancer: a step toward personalized medicine. Curr Opin Oncol 2016, 28, (3), 216-21; Haberkorn, U.; Eder, M.; Kopka, K.; Babich, JW; Eisenhut, M. New strategies in prostate cancer: prostate-specific membrane antigen (PSMA) ligands for diagnosis and therapy. Clin Cancer Res 2016, 22, (1), 9-15; Eiber, M.; Fendler, WP; Rowe, SP; Calais, J.; Hofman, MS; Maurer, T.; Schwarzenboeck, SM; Kratowchil, C.; Herrmann, K.; Giesel, FL Prostate-specific membrane antigen ligands for imaging and therapy. J NuclMed 2017, 58, (Suppl 2), 67S-76S). PSMA (i) is primarily confined to the prostate (although low levels are also detected in the neovascularization systems of numerous other solid tumors, including bladder cancer, pancreatic cancer, lung cancer, and kidney cancer, but not in normal vascular systems), and (ii) is expressed as a protein in large quantities at all stages of prostate cancer (up to 10 per cancer cell). 6 (iii) It is present on the cell surface but does not detach and enter the circulation, and (iv) it is associated with enzymatic or signal transduction activities. Furthermore, PSMA expression is further upregulated in poorly differentiated, androgen-insensitive, or metastatic cancers, and this expression is generally associated with disease progression.
[0061] The unique expression of PSMA makes it an important biomarker for prostate cancer (and several other cancers). Furthermore, PSMA represents a large extracellular target for imaging agents. PSMA is internalized upon ligand binding; therefore, it is not only an excellent target for targeted radionuclide therapy (using radionuclides that emit particles) but also for other therapeutic strategies, including tumor cell-specific delivery of immunotoxins, retargeting of immune cells, prodrug activation, PSMA vaccines, and plasmid DNA and adenovirus immunization. Due to its low expression levels in healthy tissues, PSMA also has the potential for high-dose therapy with minimal side effects.
[0062] The PSMA-binding targeting moiety of the radiolabeled complex included in the pharmaceutical compositions according to the invention can generally be a binding entity capable of selectively (and optionally irreversibly) binding to a (human) prostate-specific membrane antigen (e.g., as described in Chang Rev Urol. 2004; 6(Suppl 10): S13–S18). This PSMA-binding moiety is preferably selected by its ability to confer selective affinity for PSMA. Preferred PSMA-binding moieties are described in WO2013 / 022797A1, WO2015 / 055318A1, and EP2862857A1, which are incorporated herein by reference in their entirety.
[0063] Therefore, the PSMA targeting portion can preferably be characterized by general formula (2):
[0064] (2)
[0065] in
[0066] X is selected from O, N, S, or P.
[0067] R 3 R 4 and R 5 Each is independently selected from –COH, -CO2H, -SO2H, -SO3H, -SO4H, -PO2H, -PO3H, -PO4H2, -C(O)-(Cl-C 10 )alkyl, -C(O)-O(C1-C 10 )alkyl, -C(O)-NHR 8 , or –C(O)-NR 8 R 9 , where R 8 and R 9 Each is independently selected from H, bond, (C1-C) 10) alkylene, F, Cl, Br, I, C(O), C(S), -C(S)-NH-benzyl-, -C(O)-NH-benzyl, -C(O)-(C1-C 10 alkylene, -(CH2) p -NH, -(CH2) p -(C1-C 10 alkylene, -(CH2) p -NH-C(O)-(CH2) q -(CH) r CH2) t -NH-C(O)-(CH2) p -(CH2) p -CO-COH, -(CH2) p -CO-CO2H, -(CH2) p -C(O)NH-C[(CH2) q -COH]3、-C[(CH2) p -COH]3、-(CH2) p -C(O)NH-C[(CH2) q -CO2H]3、-C[(CH2) p -CO2H]3 or -(CH2) p -(C5-C 14 ) heteroaryl, and
[0068] b, p, q, r, and t are each an independent integer selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[0069] In the preferred PSMA targeting portion, b can be an integer selected from 1, 2, 3, 4, or 5, and R 3 R 4 and R 5 Each can be CO2H, and X can be O.
[0070] Examples of small molecule PSMA targets that can bind to the extracellular domain of PSMA include, but are not limited to: N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-S-[11C]methyl-l-cysteine (DCFBC), several urea-based peptide mimic PSMA inhibitors, as described by Boucheluchue et al. (Discov Med. 2010 Jan; 9(44): 55–61), including MIP-1095 (Hillier et al., Cancer Res. 2009 Sep 1;69(17):6932-40).
[0071] Kelly et al. (Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer. J Nucl Med. 2017 Sep;58(9):1442-1449. doi: 10.2967 / jnumed.116.188722) evaluated agents that showed affinity for both PSMA and human serum albumin (HSA). The ligands developed by Kelly et al. contain a p-(iodophenyl)butyric acid unit for HSA binding and a urea-based PSMA binding unit. Among the compounds developed by Kelly et al., radiotherapy-targeted iodine (PSMA) binds to PSMA. 131 I) Covalently connected to the HSA binding region, which in turn is directly connected to the PSMA binding structural unit through the hydrocarbon chain.
[0072] As described above, the targeting and chelating moieties typically form together a conjugate or molecule (suitable for radiolabeling). Various such conjugates / molecules are known in the art. Preferred conjugates comprising a chelating moiety and a targeting moiety capable of binding to a PSMA are disclosed in WO2018 / 215627A1, which is also incorporated herein by reference.
[0073] Preferred examples of conjugates comprising a targeting moiety and a chelating moiety include PSMA-617 (JNM2015,56:914–920 and EP2862857A1) developed by Benešová et al. according to formula (3); PSMA-I&T (Weineisen M et al., J Nucl Med. 2015; 56:1169-1176) according to formula (4); Ibu-PSMA according to formula (5); Ibu-DAB-PSMA according to formula (6); Ibu-N-PSMA according to formula (7); and Ibu-Dα-PSMA according to formula (8).
[0074] PSMA-617:
[0075] (3)
[0076] PSMA-I&T:
[0077] (4)
[0078] Ibu-PSMA:
[0079] (5)
[0080] Ibu-DAB-PSMA:
[0081] (6)
[0082] Ibu-N-PSMA:
[0083] (7)
[0084] Ibu-Dα-PSMA:
[0085] (8)
[0086] Therefore, the radiolabeled complex of the pharmaceutical composition according to the invention (comprising a radionuclide and a targeting portion connected to the chelating portion) can be obtained from compounds represented by formulas (3) to (8) above, and is preferably selected from... 225 Ac-Ibu-DAB-PSMA 225 Ac-PSMA-617 and 225 Ac-PSMA-I&T, especially 225 Ac-Ibu-DAB-PSMA, more specifically (S)-Ibu-DAB-PSMA. They all contain a DOTA chelating agent and may also be named, for example, separately. 225 Ac-DOTA-Ibu-DAB-PSMA 225 Ac-DOTA-PSMA-617 and 225 Ac-DOTA-PSMA-I&T.
[0087] The radiolabeled complex (comprising a radionuclide and a targeting portion linked to the chelating moiety) in the pharmaceutical composition is preferred. 225 Ac-Ibu-DAB-PSMA 225 Ac-PSMA-617 and 225 The concentration of Ac-PSMA-I&T is preferably from 10 nmol / mL to 150 nmol / mL, more preferably from 10 nmol / mL to 130 nmol / mL. The concentration of the prodrug (the targeting portion linked to the chelating portion) in the pharmaceutical composition is preferably from 20 µg / mL to 200 µg / mL, particularly from 30 µg / mL to 160 µg / mL.
[0088] Furthermore, in the pharmaceutical composition, 225 The Ac radionuclide is preferably present at a concentration providing volumetric radioactivity of 0.2 MBq / mL to 4 MBq / mL or 0.4 MBq / mL to 4.0 MBq / mL, preferably 1.0 MBq / mL to 4.0 MBq / mL. In another embodiment,225 Ac radionuclides are preferably present at a concentration providing volumetric radioactivity of 0.2 MBq / mL to 2 MBq / mL, more preferably 0.2 MBq / mL to 1.0 MBq / mL, and most preferably 0.3 MBq / mL to 0.8 MBq / mL.
[0089] Compounds targeting integrins
[0090] In some embodiments, the radiolabeled complex of the pharmaceutical composition according to the invention comprises a targeting portion of integrins, particularly αvβ3 integrins.
[0091] Integrins are heterodimeric glycoproteins composed of α- and β-subunits. Twenty-four different combinations of eight β-units and eighteen α-units are known. Integrins mediate cell-cell and cell-matrix interactions and transmembrane signal transduction via inside-out and outside-in signal transduction. Some integrins play important roles in the migration of endothelial cells and tumor cells during tumor-induced angiogenesis and tumor metastasis. Angiogenesis, the formation of new blood vessels from an existing vascular system, is a key step in the development and dissemination of many human tumors. Various therapeutic strategies in oncology focus on inhibiting tumor-induced angiogenesis. Regarding integrins, the roles of integrin αvβ3 and αvβ3 have received significant attention due to their prominence on proliferating vascular endothelial cells. Therefore, one of the most prominent target structures for developing radiopharmaceuticals for angiogenesis imaging is integrin αvβ3.
[0092] Tumor-induced angiogenesis can be blocked in vivo by antagonizing αvβ3 integrin with a small peptide containing the Arg-Gly-Asp (RGD) amino acid sequence. This tripeptide sequence is naturally present in extracellular matrix proteins and is the major binding site for αvβ3 integrin. Due to the selective expression of αvβ3 integrin in tumors, radiolabeled RGD peptides are attractive candidates for targeting αvβ3 integrin in tumors. Over the past decade, many radiolabeled linear and cyclic RGD peptides have been evaluated as radiotracers for tumor imaging via SPECT or PET, and also as therapeutic agents.
[0093] To allow 225 Ac is used for radiolabeling, preferably using a chelate moiety conjugated to a peptide. Any suitable chelate moiety can be used as the chelate moiety, such as those specified above, of which DOTA, DOTAGA, and Macropa are preferred. A preferred example of a conjugate comprising an RGD peptide as the targeting moiety and DOTA as the chelate moiety is DOTA-RGD according to formula (9):
[0094] DOTA-RGD:
[0095] (9)
[0096] In a preferred embodiment, the radiolabeled complex contained in the pharmaceutical composition according to the invention comprises (i) a radionuclide (Ac-225) and (ii) DOTA-RGD. Therefore, in a preferred embodiment, the radiolabeled complex (comprising a radionuclide, a targeting portion, and a chelating portion) is 225 Ac-DOTA-RGD.
[0097] The concentration of the αvβ3 targeting moiety linked to the chelating agent in the pharmaceutical composition is preferably from 10 nmol / mL to 150 nmol / mL, and more preferably from 10 nmol / mL to 130 nmol / mL.
[0098] Furthermore, in the pharmaceutical composition, 225 Ac radionuclides are preferably present at a concentration providing volumetric radioactivity of 0.2 MBq / mL to 4 MBq / mL or 0.4 MBq / mL to 4.0 MBq / mL, preferably 1.0 MBq / mL to 4.0 MBq / mL, or preferably at a concentration providing volumetric radioactivity of 0.2 MBq / mL to 2 MBq / mL, more preferably 0.2 MBq / mL to 1.0 MBq / mL, and even more preferably 0.3 MBq / mL to 0.8 MBq / mL, and most preferably 0.35 MBq / mL to 0.45 MBq / mL.
[0099] stabilizer
[0100] To provide stability against radiodegradation, the pharmaceutical composition includes a stabilizer. As used herein, the term "stabilizer" (against radiodegradation) refers to an agent that protects organic molecules from radiodegradation. In particular, the stabilizer is capable of scavenging free radicals that may be generated, for example, when a radionuclide emits gamma rays, and the gamma rays break the bonds between atoms in an organic molecule, thereby forming a free radical. Thus, the stabilizer prevents or reduces the free radicals from undergoing other chemical reactions that could result in undesirable, potentially ineffective, or even toxic molecules.
[0101] The stabilizers included in the pharmaceutical compositions according to the invention comprise sodium acetate (NaOAc) and ethanol. As shown in the accompanying examples, such formulations not only reduce the complexity of the compositions (and their preparation) but also unexpectedly yield high stability of the radiolabeled complexes.
[0102] Preferably, the concentration of sodium acetate in the pharmaceutical composition according to the invention is from 7 mg / mL to 100 mg / mL or from 9 mg / mL to 100 mg / mL, particularly from 7 mg / mL or from 9 mg / mL to 15 mg / mL or from 20 mg / mL, for example from 7 mg / mL to 15 mg / mL, more preferably from 7 mg / mL or from 9 mg / mL to 12 mg / mL, for example from 7 mg / mL to 12 mg / mL. Exemplary ranges are from 20 mg / mL to 90 mg / mL, from 30 mg / mL to 80 mg / mL, from 40 mg / mL to 70 mg / mL, or from 50 mg / mL to 60 mg / mL. Preferably, the pharmaceutical composition according to the invention contains from 9.8 mg / mL to 98.4 mg / mL of sodium acetate, which corresponds to from 2.7 mg / MBq to 6.6 mg / MBq.
[0103] As shown in the examples below, formulations containing sodium acetate at concentrations as defined above exhibit high purity and long-term stability of the radiolabeled complex.
[0104] Furthermore, the stabilizer of the pharmaceutical composition according to the invention also comprises ethanol. In a preferred embodiment, the concentration of ethanol in the pharmaceutical composition according to the invention is from 1% (vol / vol) to 30% (vol / vol), more preferably from 2% (vol / vol) to 20% (vol / vol), even more preferably from 2 vol.% to 7 vol.%, even more preferably from 3 vol.% to 5 vol.%, and most preferably from 3.5 vol.% to 4.5 vol.%.
[0105] As shown in the examples below, formulations containing ethanol and sodium acetate at concentrations defined above ensure the high purity and long-term stability of the radiolabeled complex.
[0106] In some implementations, other stabilizers may be present in addition to sodium acetate (NaOAc) and ethanol. Examples of such other stabilizers include ascorbic acid and / or its salts, such as sodium ascorbate, gentianic acid, methionine, histidine, melatonin, and Se-methionine.
[0107] In a preferred embodiment, in addition to sodium acetate (NaOAc) and ethanol, the pharmaceutical composition comprises ascorbic acid and / or its salts.
[0108] Various salts of ascorbic acid are known in the art and readily available. Generally, the term "salt" refers to an ionic assembly of cations and anions, consisting of a relevant number of cations and anions, such that the product (salt) is electrically neutral (without a net charge). In salts of ascorbic acid, these salts typically form with ascorbate anions. Preferred salts of ascorbic acid include alkali metal salts of ascorbic acid. The term "alkali metal salt" refers to a salt that produces hydroxide ions when dissolved in water. Non-limiting examples of preferred salts of ascorbic acid include sodium, potassium, calcium, magnesium, and lithium salts of ascorbic acid; for example, sodium ascorbate, sodium ascorbate phosphate, potassium ascorbate, calcium ascorbate, magnesium ascorbate, magnesium ascorbate phosphate, and lithium ascorbate. Most preferably, salts of ascorbic acid are sodium salts of ascorbic acid, particularly sodium ascorbate.
[0109] Preferably, if present in the pharmaceutical composition, the concentration of ascorbic acid salt, particularly sodium ascorbate, is from 1 mg to 100 mg / mL, preferably from 10 mg / mL to 90 mg / mL, more preferably from 10 mg / mL to 80 mg / mL, even more preferably from 10 mg / mL to 70 mg / mL, even more preferably from 10 mg / mL to 60 mg / mL, particularly preferably from 10 mg / mL to 50 mg / mL, and most preferably from 10 mg / mL to 40 mg / mL. In a preferred embodiment, the concentration of ascorbic acid salt, particularly sodium ascorbate, in the pharmaceutical composition is less than 40 mg / mL, i.e., 0 mg / mL to 40 mg / mL, 1 mg / mL to 40 mg / mL, 2 mg / mL to 40 mg / mL, 3 mg / mL to 40 mg / mL, 4 mg / mL to 40 mg / mL, 5 mg / mL to 40 mg / mL, 6 mg / mL to 40 mg / mL, 7 mg / mL to 40 mg / mL, 8 mg / mL to 40 mg / mL, 9 mg / mL to 40 mg / mL, or 10 mg / mL to 40 mg / mL.
[0110] If the pharmaceutical composition contains a salt of ascorbic acid, its concentration may be selected from 15 mg / mL to 50 mg / mL or 20 mg / mL to 50 mg / mL. In another embodiment, if the pharmaceutical composition contains a salt of ascorbic acid, its concentration may be selected from 20 mg / mL to 40 mg / mL, or preferably 30 mg / mL to 40 mg / mL. The salt of ascorbic acid is preferably sodium ascorbate.
[0111] In another embodiment, the pharmaceutical composition comprises ascorbic acid and / or ascorbic acid salts at a concentration of at least 10 mg / mL, or preferably at least 15 mg / mL, or more preferably at least 20 mg / mL, and even more preferably at least 30 mg / mL. The upper limit may be selected from 40 mg / mL or 50 mg / mL, such that the concentration range is, for example, 15 mg / mL to 50 mg / mL, or particularly 20 mg / mL to 40 mg / mL or 30 mg / mL to 40 mg / mL.
[0112] As shown in the examples below, formulations containing sodium ascorbate at concentrations defined above ensure the high purity and long-term stability of the radiolabeled complex.
[0113] Therefore, the pharmaceutical composition of the present invention comprises sodium acetate (NaOAc) and ethanol as stabilizers, and optionally contains sodium ascorbate, preferably at the concentration defined above. More preferably, sodium acetate (NaOAc), ethanol, and optionally sodium ascorbate are the only stabilizers present in the pharmaceutical composition. In other words, the stabilizers contained in the pharmaceutical composition preferably consist of sodium acetate (NaOAc), ethanol, and optionally sodium ascorbate, preferably at the concentrations defined above.
[0114] In another preferred embodiment, the pharmaceutical composition does not contain any of the following substances: gentianic acid or a salt thereof, methionine, histidine, melatonin, and Se-methionine. In another embodiment, the pharmaceutical composition does not contain ascorbic acid or a salt of ascorbic acid. Furthermore, the pharmaceutical composition may not contain any of gentianic acid or a salt thereof, ascorbic acid or a salt thereof, methionine, histidine, melatonin, and Se-methionine. In another embodiment, the pharmaceutical composition may contain only sodium acetate (NaOAc) and ethanol as stabilizers.
[0115] In a preferred embodiment, the pharmaceutical composition comprises 9.0 mg / mL to 100 mg / mL of NaOAc, 2 vol.% to 20 vol.% of ethanol, and 0 mg / mL to 40 mg / mL of Na-ascorbate.
[0116] In another preferred embodiment, the pharmaceutical composition comprises 7 mg / mL to 15 mg / mL of NaOAc, 2 vol.% to 7 vol.% (more preferably 3 vol.% to 5 vol.%) of ethanol, and 30 mg / mL to 50 mg / mL of a salt of ascorbic acid, particularly Na-ascorbate. Thus, the pharmaceutical composition may comprise 7 mg / mL to 12 mg / mL of NaOAc, 3 vol.% to 5 vol.% of ethanol, and 30 mg / mL to 40 mg / mL of a salt of ascorbic acid, particularly Na-ascorbate. Alternatively, the pharmaceutical composition may comprise 7 mg / mL to 15 mg / mL of NaOAc, 3 vol.% to 5 vol.% of ethanol, and 20 mg / mL to 40 mg / mL of Na-ascorbate. As shown in the appended examples, pharmaceutical compositions comprising the amounts of stabilizer defined above exhibit ≥94% radiochemical purity over at least 72 hours.
[0117] In a preferred embodiment, the pharmaceutical composition comprises (i) 7 mg / mL to 12 mg / mL of NaOAc, 3 vol.% to 5 vol.% of ethanol and 30 mg / mL to 40 mg / mL of Na-ascorbate, (ii) the composition does not contain a chelating agent, and further (iii) the composition does not contain any of the following substances: gentianic acid or its salts, methionine, histidine, melatonin and Se-methionine.
[0118] The pharmaceutical compositions according to the invention are preferably aqueous solutions, particularly for radiopharmaceuticals. As used herein, "aqueous solution" generally refers to a solution in which one or more solutes are in water.
[0119] In some embodiments, the pharmaceutical composition may contain additional buffers, such as citrate buffer or phosphate buffer. However, it is preferred that the pharmaceutical composition does not contain any buffers other than sodium acetate and optionally sodium ascorbate, which are present as stabilizers and also provide buffering function.
[0120] In some embodiments, the pharmaceutical composition may contain a chelating agent, such as diethylenetriaminepentaacetic acid (DTPA) or a salt thereof. As used herein, the term "chelating agent" refers to an agent suitable for chelating radioactive nuclide metal ions, such as DTPA. However, the inventors have found that the addition of a chelating agent is unnecessary. Therefore, it is preferred that the pharmaceutical composition does not contain a chelating agent, such as DTPA. DTPA is known to induce side effects such as nausea, vomiting, diarrhea, chills, fever, itching, muscle cramps, headache, dizziness, and chest pain. Therefore, it is preferred that the pharmaceutical composition does not contain DTPA.
[0121] Therefore, in a preferred embodiment, the excipients of the pharmaceutical composition are essentially composed of sodium acetate, ethanol, optionally sodium ascorbate, and water.
[0122] In a specific implementation plan, the pharmaceutical composition may consist (basically) of the following:
[0123] (a) includes 225 Radiolabeled complexes of Ac-PSMA-617;
[0124] (b) A stabilizer comprising 9 mg / mL to 100 mg / mL sodium acetate, 1.0% (vol / vol) to 30% (vol / vol) ethanol, and 0 mg / mL to 40 mg / mL sodium ascorbate; and
[0125] (c) Water.
[0126] In another specific embodiment, the pharmaceutical composition may consist (essentially) of the following:
[0127] (a) includes 225 Radiolabeled complexes of Ac-PSMA-I&T;
[0128] (b) A stabilizer comprising 9 mg / mL to 100 mg / mL sodium acetate, 1.0% (vol / vol) to 30% (vol / vol) ethanol, and 0 mg / mL to 40 mg / mL sodium ascorbate; and
[0129] (c) Water.
[0130] In yet another specific embodiment, the pharmaceutical composition may consist (essentially) of the following:
[0131] (a) includes 225 Radiolabeled complexes of Ac-Ibu-DAB-PSMA;
[0132] (b) A stabilizer comprising 9 mg / mL to 100 mg / mL sodium acetate, 1.0% (vol / vol) to 30% (vol / vol) ethanol, and 0 mg / mL to 40 mg / mL sodium ascorbate; and
[0133] (c) Water.
[0134] In yet another embodiment, the pharmaceutical composition may consist (essentially) of the following:
[0135] (a) includes 225 Radiolabeled complexes of Ac-DOTA-RGD;
[0136] (b) A stabilizer comprising 9 mg / mL to 100 mg / mL sodium acetate, 1.0% (vol / vol) to 30% (vol / vol) ethanol, and 0 mg / mL to 40 mg / mL sodium ascorbate; and
[0137] (c) Water.
[0138] In another specific embodiment, the pharmaceutical composition may consist (essentially) of the following:
[0139] (a) includes 225 Radiolabeled complexes of Ac-PSMA-617;
[0140] (b) A stabilizer comprising 7 mg / mL to 12 mg / mL sodium acetate, 1.0% (vol / vol) to 7% (vol / vol) ethanol, and 0 mg / mL to 50 mg / mL sodium ascorbate; and
[0141] (c) Water.
[0142] In another specific embodiment, the pharmaceutical composition may consist (essentially) of the following:
[0143] (a) includes 225 Radiolabeled complexes of Ac-PSMA-I&T;
[0144] (b) A stabilizer comprising 7 mg / mL to 12 mg / mL sodium acetate, 1.0% (vol / vol) to 7% (vol / vol) ethanol, and 30 mg / mL to 40 mg / mL sodium ascorbate; and
[0145] (c) Water.
[0146] In yet another specific embodiment, the pharmaceutical composition may consist (essentially) of the following:
[0147] (a) includes 225 Radiolabeled complexes of Ac-Ibu-DAB-PSMA;
[0148] (b) A stabilizer comprising 7 mg / mL to 12 mg / mL sodium acetate, 3% (vol / vol) to 5% (vol / vol) ethanol, and 30 mg / mL to 40 mg / mL sodium ascorbate; and
[0149] (c) Water.
[0150] In yet another embodiment, the pharmaceutical composition may consist (essentially) of the following:
[0151] (a) includes 225Radiolabeled complexes of Ac-DOTA-RGD;
[0152] (b) A stabilizer comprising 9 mg / mL to 10 mg / mL sodium acetate, 3.5% (vol / vol) to 4.5% (vol / vol) ethanol, and 35 mg / mL to 40 mg / mL sodium ascorbate; and
[0153] (c) Water.
[0154] In pharmaceutical compositions, radionuclides, especially 225 Ac may be present at a concentration providing volumetric radioactivity of 0.4 MBq / mL to 4.0 MBq / mL or 0.2 MBq / mL to 2 MBq / mL, preferably 1.0 MBq / mL to 4.0 MBq / mL or 0.2 MBq / mL to 1 MBq / mL, more preferably 0.3 MBq / mL to 0.8 MBq / mL, and most preferably 0.35 MBq / mL to 0.45 MBq / mL.
[0155] In some embodiments, the pharmaceutical composition is substantially free of radiolabeled complex precursors, for example, substantially free of... 225 Ac-PSMA-617 225 Ac-PSMA-I&T 225 Ac-Ibu-DAB-PSMA and 225 Ac-DOTA-RGD precursor. In some embodiments, the amount of the radiolabeled complex precursor in the pharmaceutical composition, particularly, is... 225 Ac-PSMA-617 225 Ac-PSMA-I&T 225 Ac-Ibu-DAB-PSMA and 225 The amount of the Ac-DOTA-RGD precursor does not exceed the amount of the radiolabeled complex in the final pharmaceutical composition (to be injected / infused), for example... 225 Ac-PSMA-617 225 Ac-PSMA-I&T 225 Ac-Ibu-DAB-PSMA and 225 The amount of Ac-DOTA-RGD is 5%, preferably not more than 2%, more preferably not more than 1%, and even more preferably not more than 0.5%. Even more preferably, the pharmaceutical composition is substantially free of radiolabeled complex precursors, for example, substantially free of... 225 Ac-PSMA-617 225 Ac-PSMA-I&T 225 Ac-Ibu-DAB-PSMA and 225The precursor to Ac-DOTA-RGD. In a particularly preferred embodiment, the pharmaceutical composition is substantially free of... 225 Ac-Ibu-DAB-PSMA precursor.
[0156] As shown in the accompanying examples, the pharmaceutical composition according to the invention can provide a shelf life of at least 24 hours, particularly when stored at room temperature (RT) (e.g., 23°C / 70%RH). In some embodiments, the shelf life of the pharmaceutical composition is at least 24 hours, preferably at least 48 hours, more preferably at least 72 hours, and even more preferably at least 96 hours, particularly when stored at RT.
[0157] Furthermore, the accompanying examples demonstrate that using one or more specific stabilizers as described herein can provide at least 94% of the stabilizer within at least 72 hours. 225 The radiochemical purity of Ac-labeled compounds, particularly when stored at RT. For example, for various formulations according to the invention as described herein, at least 95% radiochemical purity and ≤1.0% uncomplexed "free" compounds were found after 72 hours. 225 Ac 3+ The 225 Ac-labeled compounds. More preferably, the radiochemical purity of the pharmaceutical composition can be maintained at ≥95%, more preferably ≥96%, even more preferably ≥97%, and still more preferably ≥99%, for at least 72 hours, and without complexed "free" components. 225 Ac 3+ It can be maintained at ≤1.4%, preferably ≤1.0%, more preferably ≤0.5%, and even more preferably ≤0.25%, especially when stored at RT. For this purpose, radiochemical purity can be determined by radiometric TLC or HPLC as known in the art and described in the examples.
[0158] The formulation ensures radioactive concentrations for radiation decomposition stability of 0.2 MBq / mL to 4 MBq / mL, 0.4 MBq / mL to 4.0 MBq / mL, 0.2 MBq / mL to 2 MBq / mL, 0.2 MBq / mL to 1 MBq / mL, or 0.3 MBq / mL to 0.8 MBq / mL, or most preferably 0.35 MBq / mL to 0.45 MBq / mL, thereby ensuring a volume of 1 mL to 20 mL for radiation decomposition stability.
[0159] In a preferred embodiment, the pharmaceutical composition comprises (i) 7 mg / mL to 12 mg / mL of NaOAc, 3 vol.% to 5 vol.% of ethanol, and 30 mg / mL to 40 mg / mL of Na-ascorbate, (ii) the composition does not contain a chelating agent, (iii) the composition does not contain any of the following substances: gentianic acid or a salt thereof, methionine, histidine, melatonin, and Se-methionine, and (iv) 225 The Ac radionuclide is present in the composition at a concentration providing volumetric radioactivity of 0.3 MBq / mL to 0.8 MBq / mL, preferably 0.35 MBq / mL to 0.45 MBq / mL.
[0160] In other preferred embodiments, the pharmaceutical composition comprises (i) 7 mg / mL to 12 mg / mL of NaOAc, 3 vol.% to 5 vol.% of ethanol, and 30 mg / mL to 40 mg / mL of Na-ascorbate, (ii) the composition does not contain a chelating agent, (iii) the composition does not contain any of the following substances: gentianic acid or its salts, methionine, histidine, melatonin, and Se-methionine, (iv) 225 The Ac radionuclide is present in the composition at a concentration providing volumetric radioactivity of 0.3 MBq / mL to 0.8 MBq / mL, preferably 0.35 MBq / mL to 0.45 MBq / mL, and (v) the radiolabeled complex comprises or consists of 225 Ac(actinium-225) radionuclides and Ibu-DAB-PSMA, more preferably (S)-Ibu-DAB-PSMA.
[0161] The pharmaceutical composition is intended for intravenous (iv) use / application / administration. The pharmaceutical composition is typically stable, concentrated, and ready for immediate use.
[0162] The pharmaceutical composition according to the invention can be provided as a single-dose product, for example in a vial containing a single dose of a radiolabeled complex. For this purpose, the vial may contain about 1 ml to 25 ml of the pharmaceutical composition, preferably 1 ml to 20 ml, more preferably 1 ml to 15 ml, and even more preferably 1 ml to 10 ml. A single dose may allow delivery of 0.5 MBq ± 10% to 40 MBq ± 10% radioactivity upon injection, preferably 1 MBq ± 10% to 20 MBq ± 10% radioactivity upon injection, more preferably about 1 MBq ± 10% to 20 MBq ± 10% radioactivity upon injection, for example, 7.5 MBq ± 10% radioactivity upon injection.
[0163] Preferably, each of the stabilizers sodium acetate and ethanol present in the (final) pharmaceutical composition was already present during complex formation (radiolabeling).
[0164] As used herein, the phrase "present during complex formation" is intended to refer to such reagents / compounds present in the reaction mixture (also referred to as the "radiolabeled composition") used for complex formation (radiolabeling). To obtain the radiolabeled reaction mixture (radiolabeled composition), a solution of a radionuclide is added to a solution containing a chelating portion linked to the target portion (or vice versa). Thus, any reagents / compounds present during complex formation (radiolabeling), such as stabilizers, may be contained in the radionuclide solution, in the solution containing the chelating portion linked to the target portion, or in a separate solution to be added. After obtaining the radiolabeled composition, an elevated temperature, such as 80°C to 90°C, may be applied to the radiolabeled composition (including the reagents / compounds contained therein) for a defined time window, such as 5 minutes to 25 minutes, to promote complex formation (radiolabeling).
[0165] As described above, it is preferred that each of the stabilizers sodium acetate and ethanol present in the (final) pharmaceutical composition is already present during complex formation (radiolabeling). However, the concentration and / or weight ratio of one or more stabilizers in the radiolabeled composition (reaction mixture) during complex formation (radiolabeling) may differ from the concentration and / or weight ratio of one or more stabilizers in the (final) pharmaceutical composition. For example, one or more stabilizers present during complex formation (radiolabeling) may be added additionally after complex formation (radiolabeling).
[0166] As used herein, the phrase "after complex formation (radiolabeling)" refers to the time when the complex formation (radiolabeling) reaction is complete. For example, when an elevated temperature is applied for radiolabeling, "after complex formation (radiolabeling)" may refer to the time when the radiolabeled composition (radiolabeled reaction mixture) is no longer exposed to the elevated temperature (e.g., when ambient temperature is reached again, for example, by cooling the radiolabeled composition). In particular, "after complex formation (radiolabeling)" may refer to the formulation of the (final) pharmaceutical composition, for example, by diluting the radiolabeled mixture with water.
[0167] Therefore, it is preferred that sodium acetate and ethanol are present during complex formation (radiolabeling). It is also preferred that sodium acetate and ethanol are added after complex formation (radiolabeling). More preferably, sodium acetate and ethanol are present during complex formation (radiolabeling), and added after complex formation (radiolabeling). In other preferred embodiments, sodium ascorbate is not present during complex formation (radiolabeling). In other preferred embodiments, sodium ascorbate is added after complex formation.
[0168] Therefore, it is preferred that sodium acetate is present at a concentration of 9 mg / mL to 100 mg / mL, preferably 10 mg / mL to 100 mg / mL, for example 20 mg / mL to 90 mg / mL, 30 mg / mL to 80 mg / mL, 40 mg / mL to 70 mg / mL, or 50 mg / mL to 60 mg / mL during complex formation (i.e., in the radiolabeled composition).
[0169] Also preferably, ethanol is present at a concentration of 1% (vol / vol) to 30% (vol / vol), preferably 2% (vol / vol) to 20% (vol / vol), and more preferably 5% (vol / vol) to 10% (vol / vol) during complex formation (i.e., in the radiolabeled composition).
[0170] Medical treatment and medical use
[0171] In another aspect, the present invention also provides the use of the pharmaceutical compositions described above in medicine. For example, the pharmaceutical compositions described above may be preferably used for the treatment of cancer or (in vitro) diagnosis (e.g., by using isolated samples, such as blood samples or tumor tissue). Therefore, the present invention also provides a method for treating cancer or inducing, enhancing or prolonging an antitumor response in a subject in need, comprising administering the pharmaceutical compositions described above to the subject.
[0172] It should be understood that, for medical purposes, pharmaceutical compositions typically contain an effective amount of a radiolabeled complex. As used herein, “effective amount” means an amount of one or more agents sufficient to allow for diagnosis and / or significant induction of positive improvement in the disease to be treated. However, an “effective amount” can also be small enough to avoid serious side effects, that is, to allow for a reasonable balance between benefit and risk. An “effective amount” can vary depending on the specific condition to be diagnosed or treated, as well as the age and physical condition of the patient being treated, the severity of the condition, the duration of treatment, the nature of concomitant treatment, the nature of the specific pharmaceutically acceptable excipient or carrier used, and similar factors. Therefore, an “effective amount” can be readily determined by a physician in a given situation. Generally, an effective dose can be determined through routine experiments, such as by using animal models. Such models include, but are not limited to, rabbit, sheep, mouse, rat, dog, and non-human primate models. The therapeutic efficacy and toxicity of the radiolabeled complex can be determined through standard pharmaceutical procedures in cell cultures or laboratory animals, such as those used to determine the LD50 (the dose that is lethal to 50% of the population) and ED50 (the dose that is therapeutically effective in 50% of the population). The dose ratio between toxicity and therapeutic effect is the therapeutic index and can be expressed as the LD50 / ED50 ratio. Data obtained from cell culture assays and animal studies can be used to determine the dose range for human use. The dose of the conjugate is preferably within a range of cyclic concentrations that include an ED50 with very low or no toxicity.
[0173] As used herein, the term "diagnosis" refers to the act of identifying a disease by means of its signs and symptoms and / or by means of behaviors that identify the disease and / or, as in the context of this invention, by analyzing biomarkers (e.g., proteins) that indicate the disease.
[0174] As used herein, the term “treatment” for a disease includes prevention or protection from the disease (i.e., preventing the development of clinical symptoms); suppression of the disease (i.e., halting or suppressing the development of clinical symptoms); and / or relief of the disease (i.e., the resolution of clinical symptoms). It should be understood that because one or more eventual triggering events may be unknown or latent, it is not always possible to distinguish between “prevention” and “suppression” of a disease or condition. Therefore, the term “prophylaxis” will be understood as constituting a type of “treatment” that encompasses both “prevention” and “suppression.” Thus, the term “treatment” includes “prophylaxis.” Therefore, the term “treatment” includes both preventative treatment (before the onset of the disease) and therapeutic treatment (after the onset of the disease).
[0175] The pharmaceutical compositions described herein are typically administered parenterally. Administration may preferably be performed systemically, such as by intravenous (iv), subcutaneous, intramuscular, or intradermal injection. Alternatively, administration may be performed locally, such as by intratumoral injection. The pharmaceutical compositions described above may be administered to the recipient several times daily, every other day, weekly, or monthly.
[0176] The pharmaceutical compositions of the present invention comprising a radiolabeled complex having a targeting portion bound to PSMA can be used to treat or diagnose any cancer expressing PSMA. In particular, the presence of cells or tissues expressing PSMA can indicate prostate tumors (cells), metastatic prostate tumors (cells), kidney tumors (cells), pancreatic tumors (cells), bladder tumors (cells), and combinations thereof. Therefore, the cancer is preferably prostate cancer, pancreatic cancer, kidney cancer, or bladder cancer.
[0177] As described above, the pharmaceutical compositions of the present invention comprising a radiolabeled complex having a targeting portion that binds to αvβ3 can be used to treat or diagnose tumor-induced angiogenesis.
[0178] The pharmaceutical compositions described above can be used for imaging and therapeutic purposes, i.e., as "theragnostic" agents. As used herein, the term "theragnostic" includes "therapeutic only," "diagnostic only," and "therapeutic and diagnostic" applications. Therefore, in other aspects, the present invention also provides an (in vitro) method for detecting the presence of cancer cells and / or cancerous tissue, comprising (a) contacting said cancer cells and / or cancerous tissue with the pharmaceutical composition of the present invention, and (b) applying detection means, optionally radiographic imaging, to detect said cells and / or tissue.
[0179] In the in vivo and in vitro uses and methods of the present invention, radiographic imaging can be performed using any means and methods known in the art. Preferably, the radiographic imaging may involve positron emission tomography (PET) or single-photon emission computed tomography (SPECT). The target cells or tissues detected by radiographic imaging of the conjugates of the present invention preferably include (optionally cancerous) prostate cells or tissue, (optionally cancerous) spleen cells or tissue, or (optionally cancerous) kidney cells or tissue.
[0180] Methods for preparing pharmaceutical compositions
[0181] The present invention also provides a method for preparing a pharmaceutical composition according to the present invention.
[0182] Methods for preparing pharmaceutical compositions according to the present invention include:
[0183] (i) Formation of radiolabeled complexes; and
[0184] (ii) Formulation of pharmaceutical compositions.
[0185] The formation of the radiolabeled complex (step (i)) is achieved by radiolabeling the target portion covalently linked to the chelate portion with 225-actinium in a labeling buffer.
[0186] Therefore, in other respects, the present invention provides a method for radiolabeling a target portion covalently linked to the chelate portion using 225-actinium, comprising the following steps:
[0187] (a) will 225 Ac radionuclide, a radiolabeled precursor containing a target moiety covalently linked to the chelating portion, and a labeling buffer containing sodium acetate and ethanol are combined; and
[0188] (b) Heating the mixture for a predetermined period of time to obtain the desired temperature. 225 Ac-labeled complexes, which are... 225 Ac-labeled complexes contain 225 Ac radionuclides and target portions covalently linked to the chelate portion.
[0189] As described above, the formulation of the pharmaceutical composition (step (ii)) is achieved by adding a formulation buffer to a radiolabeled complex to obtain the final pharmaceutical composition. This final pharmaceutical composition is preferably a pharmaceutical composition according to the invention.
[0190] Therefore, in other respects, the present invention provides a method for preparing a pharmaceutical composition, comprising the following steps:
[0191] (a') A radiolabeled complex (radiolabel) is formed by heating a radiolabeled solution for a defined time, the radiolabeled solution comprising (i) 225 (i) an Ac(actinium-225) radionuclide, (ii) a radiolabeled precursor containing a target moiety covalently linked to the chelating moiety, and (iii) a radiolabeled buffer containing sodium acetate (NaOAc) and ethanol; and
[0192] (b') The pharmaceutical composition is formulated by adding a formulation buffer containing water, particularly water for injection, sodium acetate and ethanol, and optionally a salt of ascorbic acid, particularly Na-ascorbate;
[0193] (c') optionally apply the obtained experience 225 The solution of the Ac-labeled complex was sterilized and filtered.
[0194] It should be understood that the above detailed description is correspondingly applicable to methods for radiolabeling the target portion covalently linked to the chelate portion with 225-actinium, and to methods for preparing pharmaceutical compositions according to the invention. For example, the detailed embodiments described above for radiolabeled complexes of pharmaceutical compositions are correspondingly applicable to methods for radiolabeling the target portion covalently linked to the chelate portion with 225-actinium, and to methods for preparing pharmaceutical compositions according to the invention.
[0195] Therefore, step (i), namely the formation of the radiolabeled complex, is preferably carried out in a radiolabeled composition comprising (or substantially comprising) the radionuclide as described above and a targeting portion connected to the chelating portion; and a radiolabeled buffer comprising sodium acetate and ethanol.
[0196] In the radiolabeled compositions obtained in steps (a) and / or (a'), sodium acetate is preferably present at a concentration of 9 mg / mL to 100 mg / mL, more preferably 20 mg / mL to 90 mg / mL, 30 mg / mL to 80 mg / mL, even more preferably 40 mg / mL to 70 mg / mL, and still more preferably 50 mg / mL to 60 mg / mL. Preferably, the radiolabeled composition contains 9.8 mg / mL to 98.4 mg / mL of sodium acetate, which corresponds to 2.7 mg / MBq to 6.6 mg / MBq.
[0197] Furthermore, in the radiolabeled compositions obtained in step (a) and / or step (a') respectively, ethanol is present at a concentration of 1% (vol / vol) to 30% (vol / vol), preferably 2% (vol / vol) to 20% (vol / vol), more preferably 3% (vol / vol) to 15% (vol / vol), and even more preferably 5% (vol / vol) to 10% (vol / vol).
[0198] In steps (a) and / or (a') (the radiolabeling step), respectively, the radionuclide solution (containing, for example, in HCl) is combined... 225 A radiolabeled reaction mixture (radiolabeled composition) is obtained by combining a solution containing a target portion linked to the chelating portion (AcCl3), a radiolabeled precursor, and a radiolabeled buffer containing sodium acetate and ethanol as stabilizers. Preferably, during the radiolabeling process (steps (a) and / or (b) of the radiolabeling method, and step (a') of the method for preparing the pharmaceutical composition, respectively), the formation of the radiolabeled complex (radiolabeling) is carried out in an aqueous solution.
[0199] Preferably, the radiolabeling composition in step (a) and / or step (a') has a pH of about 4.0 to 5.5, more preferably about 4.5 to 5.0. A buffer solution is used to maintain this favorable pH range. Preferably, the radiolabeling buffer solution has a pH of about 6.0 to 9.0, more preferably about 7 to 8, more preferably about 7.0. Using the radiolabeling buffer solution in step (a) and / or step (a') has the advantage that even if the Ac( 225 The amount of chloride solution can be varied as needed to maintain pH.
[0200] Preferably, sodium acetate and ethanol are the only stabilizers present during the radiolabeling steps (a / b) and (a'), respectively. In particular, it is preferred that the radiolabeling composition does not contain salts of ascorbic acid, especially Na-ascorbate, and / or does not contain any other stabilizers, such as gentianic acid. Therefore, in a preferred embodiment, the radiolabeling buffer contains sodium acetate and ethanol, and preferably does not contain any other stabilizers, such as salts of ascorbic acid, especially Na-ascorbate, or gentianic acid. More preferably, the labeling buffer consists essentially of sodium acetate, ethanol, and water.
[0201] In the radiolabeling step, particularly in step (a) and / or step (a'), the precursor compound (the target portion linked to the chelating portion) used to form the radiolabeled complex may be as described above (regarding the pharmaceutical composition).
[0202] Therefore, as described above, in the radiolabeling step, particularly in step (a) and / or step (a'), the precursor compound (the targeting portion connected to the chelating portion) used to form the radiolabeled complex may contain a targeting portion capable of binding to PSMA or αvβ3 integrin.
[0203] Furthermore, the precursor compound (target portion connected to the chelating portion) used in the radiolabeling step, particularly in step (a) and / or step (a'), may contain a target portion capable of binding to the somatostatin receptor; wherein the radiolabeling step is respectively the method of the present invention for radiolabeling the target portion covalently connected to the chelating portion with 225-actinium, and the method for preparing a pharmaceutical composition to form a radiolabeled complex.
[0204] Somatostatin receptors are present in numerous tumors, particularly neuroendocrine tumors, such as gastrointestinal and pancreatic neuroendocrine tumors, carcinoid tumors, pheochromocytomas, paragangliomas, medullary thyroid carcinomas, pulmonary neuroendocrine tumors, thymic neuroendocrine tumors, carcinoid tumors or pancreatic neuroendocrine tumors, pituitary adenomas, adrenal adenomas, Merkel cell carcinomas, breast cancer, non-Hodgkin lymphomas, Hodgkin lymphomas, head and neck tumors, urothelial carcinoma (bladder), renal cell carcinoma, hepatocellular carcinoma, GIST, neuroblastoma, and bile duct tumors. Cervical cancer, Ewing sarcoma, osteosarcoma, small cell lung cancer (SCLC), prostate cancer, melanoma, meningioma, glioma, medulloblastoma, hemangioblastoma, supratentorial primitive neuroectodermal tumor, olfactory neuroblastoma, functional prostate carcinoid, insulinoma, gastrinoma, vasoactive intestinal peptide (VIP) tumor, glucagonoma, serotoninoma, histaminema, ACTH tumor, pheochromocytoma, and somatostatinoma.
[0205] Conjugates comprising a chelating moiety and a targeting moiety capable of binding to the somatostatin receptor may, for example, be selected from DOTA-OC ([DOTA... 0 , D-Phe 1 ]octreotride), DOTATOC([DOTA 0 , D-Phe 1 Tyr 3 ] octreotride; INN: edotreotide), DOTANOC ([DOTA 0 , D-Phe 1 , 1-Nal 3 ]octreotride)、DOTATATE([DOTA 0 , D-Phe 1 Tyr 3 ]octreotate; INN:oxodotreotide), DOTALAN([DOTA 0 , D-β-Nal 3 ]octreotride), DOTAVAP([DOTA 0 , D-Phe 1 Tyr 3 ]vapreotide), satoreotide trizoxetan and satoreotide tetraxetan and DOTA-JR11 (DOTA-(Cpa-c(D-Cys-Aph(Hor)-d-Aph(Cbm)-Lys-Thr-Cys)D-Tyr-NH2)).
[0206] Therefore, the molecules comprising chelating and targeting portions used in the radiolabeling method of the present invention can be selected from, for example, DOTATOC (which may be represented by Formula 10), DOTA-JR11 (which may be represented by Formula 11), and DOTATATE (which may be represented by Formula 12) to provide effective targeting of somatostatin receptors. 225 Ac-labeled radiopharmaceuticals.
[0207] DOTATOC:
[0208] (10)
[0209] DOTA-JR11:
[0210] (11)
[0211] DOTATATE:
[0212] (12)
[0213] Furthermore, the targeting portion of the precursor compound connected to the chelating portion in step (a) and / or step (a') can target many other receptors known to be expressed on different tumor cells, in particular the radiolabeling step of the present invention, which is a method for radiolabeling the targeting portion covalently connected to the chelating portion with actinium-225 and a method for preparing a pharmaceutical composition.
[0214] In one implementation, the targeting portion may be a folate conjugate that binds to a folate receptor, such as that overexpressed in ovarian cancer.
[0215] In another embodiment, the targeting portion, linked to the chelating portion, in the precursor compounds used for the radiolabeling step, particularly in steps (a) and / or (a'), respectively, targets the CCK2-receptor (cholecystokinin), which is overexpressed in several types of human cancers, such as medullary thyroid carcinoma, small cell lung cancer, and stromal ovarian carcinoma. A variety of peptide ligands for targeting the CCK2-receptor have been synthesized and characterized, all of which share the C-terminal CCK receptor-binding tetrapeptide sequence Trp-Met-Asp-Phe-NH2.Examples of CCK receptor ligands are gastrin analogs, such as Sargastrin (Gln-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Nle-Asp-Phe-NH2), Minigastrin 0 (MG-0) (D-Glu-(Glu)5-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2), Minigastrin 11 (MG-11) (D-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2), cyclo-Minigastrin 1 (cyclo-MG1) (cyclo[γ-D-Glu-Ala-Tyr-D-Lys]-Trp-Met-Asp-Phe-NH2), and cyclo-Minigastrin 2 (cyclo-MG2). (cyclo[γ-D-Glu-Ala-Tyr-D-Lys]-Trp-Nle-Asp-Phe-NH2), Demogastrin 1 (D-Glu-(Glu)5-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2), Demogastrin 2 (D-Glu-(Glu)5-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2), H2-Met (His-His-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2), H2-Nle (His-His-Glu-Ala-Tyr-Gly-Trp-Nle-Asp-Phe-NH2), H6-Met (His)6-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2); and CCK8 analogs, such as CCK8(D-Asp-Tyr-Met-Gly-Trp-Met-Asp-Phe-NH2), CCK8(Nle)(D-Asp-Tyr-Nle-Gly-Trp-Nle-Asp-Phe-NH2), sCCK8(D-Asp-Tyr(OSO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2), and sCCK8[Phe]. 2 (p-CH2SO3H), Nle 3,6 ] (D-Asp-Phe(p-CH2SO3H)-Nle-Gly-Trp-Nle-Asp-Phe-NH2), sCCK8[Phe 2 (p-CH2SO3H), HPG3,6 ] (D-Asp-Phe(p-CH2SO3H)-HPG-Gly-Trp-HPG-Asp-Phe-NH2).
[0216] The appropriate chelating fraction as specified above can be used. 225 Ac radiolabels CCK receptor-targeting peptides, among which DOTA, DOTAGA, and DOTAM are preferred.
[0217] In another embodiment, the targeting portion attached to the chelating moiety in the radiolabeling step, particularly in the precursor compounds of steps (a) and / or (a'), respectively, can target the neurotensin receptor 1 (NTR1). NTR1 is overexpressed in pancreatic ductal adenocarcinoma, one of the deadliest cancers. Therefore, radiopharmaceuticals can target NTR1, particularly using radiolabeled NTR1 antagonists for cancer diagnosis or treatment. NTR1 antagonists, such as SR142948A and SR48692, can be attached to a suitable chelating moiety as specified above, which is appropriately coordinated. 225 Ac.
[0218] In another embodiment, the targeting portion attached to the chelating moiety in the radiolabeling step, particularly in the precursor compounds of steps (a) and / or (a'), respectively, can target the glucagon-like peptide-1 (GLP-1) receptor. The GLP-1 receptor is overexpressed in substantially all benign insulinomas as well as gastrinomas. Benign insulinomas, produced by the β cells of the pancreas and existing in the form of small nodules, secrete insulin, leading to potentially life-threatening hypoglycemia. For example, peptides based on the 39-mer peptide exendin-4 can be used with a suitable chelating moiety as described herein. 225 Ac-labeled to provide radiopharmaceuticals targeting the GLP-1 receptor, with exendin-4 being a GLP-1 receptor agonist.
[0219] In another embodiment, the targeting portion attached to the chelating portion in the radiolabeling step, particularly in the precursor compound in steps (a) and / or (a') of the method of the invention, can target the gastrin-releasing peptide (GRP) receptor. The GRP receptor has been identified in major human tumors, such as breast and prostate cancer. Bufotin is a fourteen-peptide neurohormone and an amphibian homolog of mammalian GRP (27-meric peptide). Several bufotin analogues and bufotin antagonists can be used with appropriate chelating portions as defined herein. 225 Ac labeling to deliver radiopharmaceuticals targeting GRP receptors.
[0220] In another embodiment, the targeting portion attached to the chelating portion in the radiolabeling step, particularly in the precursor compound in steps (a) and / or (a') of the method of the invention, can target the neurokinin type 1 receptor. The neurokinin type 1 receptor is persistently overexpressed on glioma cells and tumor angiogenesis (Hennig IM et al., Int J Cancer 1995; 61: 786-792). The 11-amino acid peptide P substance (Arg ProLys Pro Gln Gln Phe Phe Gly Leu Met) acting via the neurokinin type 1 receptor can be suitably chelated using a suitable chelating portion as defined herein, such as DOTAGA, with... 225 Ac is radiolabeled, and the chelated portion coordinates with a radionuclide to provide a radiopharmaceutical that targets, for example, the neurokinin type 1 receptor expressed on malignant gliomas.
[0221] Preferably, the molecule containing the chelating portion and the targeting portion used in the (radiolabeling) method of the present invention may be selected from PSMA-I&T, PSMA-617, Ibu-DAB-PSMA, DOTA-RGD, DOTATOC, DOTA-JR11 and DOTATATE, especially Ibu-DAB-PSMA with a DOTA chelating agent, and more particularly (S)-Ibu-DAB-PSMA with a DOTA chelating agent.
[0222] Particularly preferred are radiolabeled complexes (containing a radionuclide, a targeting moiety, and a coordinating element). 225 The chelate portion of Ac radionuclides is 225 Ac-DOTATOC( 225 Ac-edotreotide) 225 Ac-DOTA-JR11 225 Ac-DOTA-RGD, 225 Ac-Ibu-DAB-PSMA (especially) 225 Ac-DOTA-Ibu-DAB-PSMA (albumin-binding unit, which is conjugated to the target moiety via a linker unit composed of diaminobutyric acid (DAB) and lysine residues, and contains a DOTA chelator) 225 Ac-DOTA-PSMA-617 or 225 Ac-PSMA-I&T, especially 225 Ac-DOTA-Ibu-DAB-PSMA, more specifically... 225 Ac-DOTA-(S)-Ibu-DAB-PSMA.
[0223] Preferably, in the radiolabeling composition used in the radiolabeling step, particularly in step (a) and / or step (a') for forming the radiolabeled complex, the actinium-225 radionuclide is present at a concentration providing volumetric radioactivity of 0.2 MBq / mL to 2 MBq / mL, 0.2 MBq / mL to 1 MBq / mL, or 0.3 MBq / mL to 0.8 MBq / mL, or in another embodiment, at a concentration providing volumetric radioactivity of 0.4 MBq / mL to 4.0 MBq / mL, preferably 0.5 MBq / mL to 3.0 MBq / mL, more preferably 0.6 MBq / mL to 2.0 MBq / mL, and even more preferably 0.7 MBq / mL to 3.0 MBq / mL, for example, about 0.8 MBq / mL.
[0224] In the radiolabeled compositions obtained in steps (a) and / or (a'), the precursor compound (the target portion linked to the chelating moiety) is preferably present at a concentration of 10 nmol / mL to 150 nmol / mL, more preferably 10 nmol / mL to 130 nmol / mL, and more preferably 11 nmol / mL to 129 nmol / mL, which corresponds to 13.7 nmol / MBq to 41.2 nmol / MBq. The concentration of the target portion linked to the chelating moiety is preferably 20 µg / mL to 200 µg / mL, particularly 30 µg / mL to 160 µg / mL.
[0225] After obtaining the radiolabeled composition in steps (a) and / or (a'), respectively, an elevated temperature can be applied to the radiolabeled composition within a defined time window, particularly to promote complex formation (radiolabeling). For example, in steps (b) (the radiolabeling method as described herein) and (a') (the method for preparing a pharmaceutical composition as described herein), a temperature of 60°C to 120°C, preferably 70°C to 110°C, more preferably 80°C to 100°C, even more preferably 80°C to 95°C, most preferably 85°C to 90°C, for example, about 87°C, can be applied to the radiolabeled composition. Therefore, steps (b) and (a') are particularly preferably performed at a temperature of 87 ± 4°C. The elevated temperature can be applied within a defined time window, preferably 5 minutes to 30 minutes, more preferably 8 minutes to 25 minutes, to obtain the radiolabeled composition. 225 Ac-labeled complexes, the complexes containing 225 Ac radionuclides and target portions covalently linked to the chelate portion.
[0226] As shown in the examples below, the radiolabeling method of the present invention can achieve a radiochemical yield of >99% and a radiochemical purity of >95% at the end of the synthesis.
[0227] In step (b') of the method for preparing the pharmaceutical composition, the (final) pharmaceutical composition is formulated, for example by diluting the radiolabeled mixture with a formulation buffer and water, particularly water for injection. In this regard, it should be noted that it is not necessary to remove the reaction mixture generated by the labeling reaction, and it is not necessary to purify or separate the labeled product prior to formulation.
[0228] The formulation buffer contains sodium acetate and ethanol, and optionally contains a salt of ascorbic acid, particularly Na-ascorbate. Therefore, it is preferred that sodium acetate and ethanol are present during the formation of the radiolabeled complex (step (a')) and additionally added during the formulation of the pharmaceutical composition (step (b')).
[0229] Preferably, a formulation buffer is added in step (b'), which is essentially composed of water, particularly water for injection, sodium acetate, ethanol and sodium ascorbate.
[0230] Preferably, in step (b'), a formulation buffer comprising sodium acetate, ethanol, and optionally a salt containing ascorbic acid, particularly sodium ascorbate, is added in an amount such that the concentration of NaOAc in the formulation obtained in step (b') (by adding the formulation buffer and water, particularly water for injection) is from 9.0 mg / mL to 100 mg / mL. More preferably, the composition obtained in step (b') comprises 9.8 mg / mL to 98.4 mg / mL of sodium acetate (corresponding to 2.7 mg / MBq to 65.6 mg / MBq) or 7 mg / mL to 20 mg / mL, 7 mg / mL to 15 mg / mL, or 7 mg / mL to 12 mg / mL of sodium acetate, preferably 7 mg / mL to 12 mg / mL of sodium acetate. Preferably, the concentration of ethanol in the formulation obtained in step (b') is 2 vol.% to 20 vol.%, more preferably 2 vol.% to 7 vol.%, more preferably 3 vol.% to 5 vol.%, and the concentration of ascorbic acid salt, particularly sodium ascorbate, in the (final) formulation obtained in step (b') is less than 40 mg / mL, i.e., 0 mg / mL to 40 mg / mL, which corresponds to 0 mg / MBq to 9 mg / MBq, or 20 mg / mL to 40 mg / mL or 30 mg / mL to 40 mg / mL. Thus, the composition obtained in step (b') may more preferably contain 7 mg / mL to 12 mg / mL of sodium acetate, the concentration of ethanol in the formulation obtained in step (b') may more preferably be 3 vol.% to 5 vol.%, and the concentration of ascorbic acid salt, particularly sodium ascorbate, in the (final) formulation obtained in step (b') may more preferably be 30 mg / mL to 40 mg / mL.
[0231] Preferably, sodium acetate and ethanol are the only stabilizers present during the radiolabeling step (step (a) or step (a')), and sodium acetate and ethanol, along with optional salts of ascorbic acid, particularly sodium ascorbate, are the only stabilizers present during the formulation of the pharmaceutical composition (step (b')). In other words, preferably, no other stabilizers are used throughout the entire process, i.e., in the radiolabeling step (a) and / or step (a'), and in the formulation step of the pharmaceutical composition (step (b')), except for sodium acetate and ethanol, and optional salts of ascorbic acid, particularly sodium ascorbate.
[0232] Preferably, no chelating agent, such as DTPA, is added to the pharmaceutical composition during the formulation step.
[0233] However, in some embodiments, other diluents (e.g., saline) may also be added. In this way, a final volume (and concentration) of the pharmaceutical composition can be achieved, for example, as a ready-to-use pharmaceutical composition, such as as a single-dose product. For this purpose, a final volume of about 1 ml to 20 ml, preferably 1 ml to 10 ml, of the pharmaceutical composition can be achieved by appropriate dilution (and optionally by adding other pharmaceutically acceptable components).
[0234] As shown in the examples below, the (pharmaceutical) composition obtained by the method according to the invention has a radiochemical yield of ≥94% over a period of at least 72 hours.
[0235] According to a preferred embodiment, the pharmaceutical composition is administered parenterally, particularly via intravenous or intratumoral injection, and is accordingly formulated in liquid or lyophilized form for parenteral administration. The parenteral formulation may be stored in vials, IV bags, ampoules, cartridges, or pre-filled syringes and may be administered as an injection, inhaler, or aerosol, with injection being preferred.
[0236] Liquid pharmaceutical compositions administered by injection, and particularly by intravenous, more preferably intravenous (iv) injection, should preferably be sterile and stable under the conditions of manufacture and storage. Such compositions are typically formulated as non-enteric acceptable aqueous solutions that are pyrogen-free, have a suitable pH, are isotonic, and maintain the stability of one or more active ingredients.
[0237] Pharmaceutical compositions may contain pharmaceutically acceptable excipients, diluents, or carriers. As used herein, the term "pharmaceutically acceptable" means a compound or agent that is compatible with the components of the pharmaceutical composition, particularly the active (anticancer) compound, and does not interfere with and / or substantially reduce its therapeutic activity. Pharmaceutically acceptable carriers preferably have sufficiently high purity and sufficiently low toxicity to be suitable for administration to the subject of treatment.
[0238] For liquid pharmaceutical compositions, suitable pharmaceutically acceptable excipients and carriers include water, typically pyrogen-free water; isotonic saline or buffered (aqueous) solutions, such as phosphate, citrate, etc. In particular, for injection of the (pharmaceutical) composition, water or preferably a buffer solution, more preferably an aqueous buffer solution, may be used, which may contain a sodium salt, such as at least 50 mM sodium salt, a calcium salt, such as at least 0.01 mM calcium salt, and optionally a potassium salt, such as at least 3 mM potassium salt.
[0239] Sodium, calcium, and optionally potassium salts may exist as their halides, such as chlorides, iodides, or bromides, or as their hydroxides, carbonates, bicarbonates, or sulfates. Not limited thereto, examples of sodium salts include, for example, NaCl, NaI, NaBr, Na₂CO₃, NaHCO₃, and Na₂SO₄; examples of optional potassium salts include, for example, KCl, KI, KBr, K₂CO₃, KHCO₃, and K₂SO₄; and examples of calcium salts include, for example, CaCl₂, CaI₂, CaBr₂, CaCO₃, CaSO₄, and Ca(OH)₂. Furthermore, the organic anions of the above cations may be included in the buffer solution.
[0240] Buffer solutions suitable for the injection purposes defined above may contain salts selected from sodium chloride (NaCl), calcium chloride (CaCl2), and optionally potassium chloride (KCl), wherein other anions may be present in addition to chlorides. Typically, the salts in the injection buffer are present at a concentration of at least 50 mM sodium chloride (NaCl), at least 3 mM potassium chloride (KCl), and at least 0.01 mM calcium chloride (CaCl2). The injection buffer may be hypertonic, isotonic, or hypotonic for a specific reference medium; that is, the buffer may have a higher, the same, or lower salt content for a specific reference medium, wherein the concentrations of the aforementioned salts are preferably used, which will not cause cell damage due to osmosis or other concentration effects.
[0241] The pharmaceutical composition may be provided in lyophilized form. The lyophilized pharmaceutical composition is preferably reconstituted in a suitable buffer solution, advantageously based on an aqueous carrier, prior to administration.
[0242] The present invention also provides pharmaceutical compositions obtained by the method of the present invention as described above. These pharmaceutical compositions generally exhibit the characteristics of the pharmaceutical compositions described above. The inventors have discovered that the pharmaceutical compositions obtained by the method of the present invention possess excellent stability.
[0243] As described above, the pharmaceutical composition also provides for use in the preparation of medicaments for treating cancer. Example
[0244] The following presents specific embodiments illustrating various embodiments and aspects of the invention. However, the invention should not be limited in scope to the specific embodiments described herein. The following preparations and examples are provided to enable those skilled in the art to more clearly understand and practice the invention. However, the invention is not limited in scope to the illustrated embodiments, which are intended only to illustrate a single aspect of the invention, and functionally equivalent methods are within the scope of the invention. In fact, various modifications to the invention, in addition to those described herein, will become apparent to those skilled in the art from the foregoing description and the examples below. All such modifications fall within the scope of the appended claims.
[0245] Example 1: Various buffering systems for [ 225 Effect of Ac]Ac-DOTA-PSMA on radiolabeled yield
[0246] In radiolabeled reactions, various buffer systems of different types and concentrations were studied regarding […]. 225 The radiolabeling yield of Ac]Ac-DOTA-PSMA. The conjugate used in the labeling study was Ibu-DAB-PSMA.
[0247] Radiolabeling was performed using a certified heating block (Thermo Fisher Scientific Inc., USA). For this purpose, test buffer (100 µl / MBq to 200 µl / MBq) was prepared. 225 Ac]AcCl3), ethanol (10% to 30% of the labeled solution volume), and chemical DOTA precursor (approximately 14 nmol / MBq of [AcCl3] 225 Ac]AcCl3) was directly added to a radionuclide precursor containing 0.04 M HCl (40 MBq / mL). 225 The reaction mixture was placed in a 2 mL vial of AcCl3 (ITM Medical Isotopes GmbH, Munich, Germany). The reaction mixture was heated at 87°C for 8 to 25 minutes to obtain the desired temperature. 225 Ac-labeled DOTA-PSMA. Free actinid radionuclides were determined using radiometric thin-layer chromatography (TLC) and radiometric-HPLC as described below. 225 Ac-labeled DOTA-PSMA and impurities.
[0248] Thin-layer chromatography (TLC):
[0249] A silica-on-aluminum strip 60 F254 (Merck Millipore) and a validated ScanRAM Radiograph with LAURA software (both from LabLogic Systems Ltd.) were used for radiometric thin-layer chromatography. Approximately 5 kBq or 5 µL of the Ac-225-labeled substance was spotted onto the TLC strip, and developed in the first step with 0.1 M sodium citrate (pH 7.5). After drying in an air stream, the TLC strip was developed again in the second step with a 0.1 M ammonium acetate-acetonitrile mixture (1:1). The TLC strip was read on a radiometric imager no earlier than 6 hours, ideally only 24 hours after development, to ensure decay equilibrium was reached at the time of measurement. Alternatively, the TLC strip was cut into pieces, and the Fr-221 gamma emission line was measured on an HPGe gamma detector no earlier than 1 hour after development, once Ac-225 / Fr-221 equilibrium was established. For radiolabeled compounds, Rf values were determined to be 0.4 to 0.6. 225 Ac]Ac citrate determination Rf value = 0.8 to 0.9, and for insoluble... 225 The Rf value for Ac colloid determination is 0.001. If only the citrate method is used, the Rf value for radiolabeled substances is Rf = 0.0 to 0.1.
[0250] Radiation-HPLC:
[0251] Radio-UV / VIS-HPLC was performed on a validated Agilent Infinity II system equipped with a connected radiodetector (GABI, Raytest) and a fraction collector (Agilent). Analysis of radiodecomposition products and uncomplexed Ac-225 was performed on a Waters XSelect CSH C18 XP, 150 x 2.1 mm, 2.5 µm column at 50 °C using a gradient elution of ammonium formate, acetonitrile, and DTPA. Fractions were collected in the fraction collector for 1 min or 0.5 min throughout the HPLC run. After Ac-225 / Fr-221 equilibration (1 hour after fraction collection), the Fr-221 gamma emission line was quantified in an HPGe gamma detector. Based on the Fr-221 activity in the collected fractions, the HPLC chromatogram was subsequently reconstructed, and the radiochemical purity of the Ac-225-labeled compounds was determined. For uncomplexed “free” Fr-225… 225 Ac 3+ The "total of impurities" and molecular peaks were distinguished.
[0252] Activity measurements were performed using a certified activity meter (ISOMED 2010, NUVIA Instruments GmbH). Gamma spectroscopy measurements were performed using a nitrogen-cooled HPGe (high-purity germanium) detector from ORTEC.
[0253] The test buffer system and results are shown in Table 1 below:
[0254] Table 1: Labeling yield and radiochemical purity (RCP) of Ac-225-DOTA-PSMA in different buffer systems
[0255]
[0256] M: Molar concentration (mol / L); NaOAc: Sodium acetate; EtOH: Ethanol; Ac: Actinium-225; PSMA: Ibu-DAB-PSMA; EOS: End of synthesis; RAC: Radioactive concentration; RCP: Radiochemical purity; nd: Not determined.
[0257] The labeling results shown in Table 1 indicate that using labeling buffers containing 0.6 M to 3 M sodium acetate solutions (corresponding to 2.7 mg / MBq to 65.6 mg / MBq or 9.8 mg / mL to 98.4 mg / mL sodium acetate, respectively) and 5% to 30% ethanol (see Labeling Solutions #1.2 to 1.7), >96% radiochemical purity and <0.3% free Ac content can be achieved at the end of the synthesis.
[0258] In contrast, the labeled solution containing only NaOAc as a stabilizer (#1.8) provided <96% radiochemical activity and increased free Ac content (0.6%). Notably, the labeled solutions containing Na-ascorbate as a stabilizer (#1.9 to 1.11), or containing a combination of NaOAc and Na-ascorbate as stabilizers (#1.12 to 1.15), provided less favorable results, with radiochemical purity <96% and free Ac >1.1%.
[0259] Example 2: Various formulations regarding [ 225 The protective effect of Ac]Ac-DOTA-PSMA on self-radiative decomposition
[0260] Next, various formulations of different types and concentrations were tested regarding [ 225 Ac]Ac-DOTA-PSMA (through Ac]Ac-DOTA-PSMA (through Ac) 225 The protective effect of Ac-labeled DOTA-Ibu-DAB-PSMA on radiochemical stability over a 48-hour period.
[0261] For this purpose, the reaction mixture from Example 1 (radiolabeled according to #1.7) was diluted in a reaction vial with formulation buffer, transferred to a product vial by sterile filtration, and the shelf life was determined in stability studies by periodic analysis at predetermined time points (24 hours, 48 hours).
[0262] The tested formulations and results are shown in Table 2 below. The conjugate used in the labeling and formulation studies was Ibu-DAB-PSMA (DOTA-Ibu-DAB-PSMA).
[0263] Table 2: Radiolabeled according to #1.7 225 Stability study of Ac]Ac-DOTA-PSMA in different formulations
[0264]
[0265]
[0266] M: Molar concentration (mol / L); NaOAc: Sodium acetate; EtOH: Ethanol; Ac: Actinium-225; PSMA: Ibu-DAB-PSMA; EOS: End of synthesis; RAC: Radioactive concentration; RCP: Radiochemical purity; nd: Not determined.
[0267] The results shown in Table 2 indicate that considerable radiodegradation was observed after 48 hours if the formulation did not contain ethanol (see #2.8 and #2.9). In the absence of ethanol, radiodegradation remained considerable even when the composition contained Na-ascorbate, particularly after 48 hours (see #2.8). Conversely, a strong protective effect against radiodegradation was observed when the composition contained both NaOAc and ethanol (see #2.1 to #2.7), particularly at 48 hours, even in the absence of Na-ascorbate in the composition (see #2.1).
[0268] Example 3: Containing different concentrations of [ 225 Protective effects of various formulations of Ac]Ac-DOTA-PSMA
[0269] In this study, samples containing different amounts of... 225 Ac-marked DOTA-PSMA (via 225 Various formulations of Ac-labeled Ibu-DAB-PSMA regarding [ 225 The protective effect of Ac]Ac-DOTA-PSMA on radiochemical stability over a period of up to 96 hours.
[0270] For this purpose, the reaction mixture from Example 1 (radiolabeled according to #1.7) was diluted in a reaction vial with formulation buffer, transferred to a product vial by sterile filtration, and the shelf life was determined in stability studies by periodic analysis at predetermined time points (24 hours, 48 hours, 72 hours, and 96 hours).
[0271] The tested formulations and results are shown in Table 3 below.
[0272] Table 3: Radiolabeled according to #1.7 225 Stability study of Ac]Ac-DOTA-PSMA in different formulations
[0273]
[0274]
[0275] M: Molar concentration (mol / L); NaOAc: Sodium acetate; EtOH: Ethanol; Ac: Actinium-225; PSMA = Ibu-DAB-PSMA; EOS: End of synthesis; RAC: Radioactive concentration; ART: Activity reference time; RCP: Radiochemical purity; nd: Not determined.
[0276] The results shown in Table 3 indicate that even when using different concentrations of [ 225 Ac]Ac-DOTA-PSMA, using a formulation containing NaOAc, ethanol, and sodium ascorbate, exhibited strong protection against radiodegradation up to 96 hours post-synthesis. Specifically, all tested formulations achieved >95% radiochemical purity at 72 hours, and >94% (94.5%) radiochemical purity was still observed at 96 hours (see #3.4).
[0277] Example 4: Various [containers with different radioactive concentrations] 225 The protective effect of Ac]Ac-DOTA-PSMA formulations
[0278] In this study, various formulations containing different concentrations of radioactivity were tested regarding [ 225 Ac]Ac-DOTA-PSMA (through Ac]Ac-DOTA-PSMA (through Ac) 225 Protective effect of Ac-labeled Ibu-DAB-PSMA on radiochemical stability over a period of up to 48 hours.
[0279] For this purpose, the reaction mixture from Example 1 (radiolabeled according to #1.7) was diluted in a reaction vial with formulation buffer, transferred to a product vial by sterile filtration, and the shelf life was determined in the stability study by citrate TLC and HPLC-FC analysis at predetermined time points (24 hours, 48 hours).
[0280] The tested formulations and results are shown in Table 4 below.
[0281] Table 4: Preparations containing different radioactive concentrations stored at RT for up to 48 hours [ 225 Stability Study of Ac]Ac-DOTA-PSMA
[0282]
[0283] M: Molar concentration (mol / L); NaOAc: Sodium acetate; EtOH: Ethanol; Ac: Actinium-225; PSMA = Ibu-DAB-PSMA; EOS: End of synthesis; RAC: Radioactive concentration; RCP: Radiochemical purity.
[0284] *All samples had the same EOS results because they were diluted from a single bulk label solution at the end of the synthesis.
[0285] The results shown in Table 4 demonstrate that, even with different radioactive concentrations, the formulations containing NaOAc, ethanol, and sodium ascorbate exhibited strong protection against radiodegradation up to 48 hours post-synthesis. Specifically, at 48 hours, all tested formulations achieved >95% radiochemical purity, while the content of free (uncomplexed) Ac in the final composition was ≤0.9%.
[0286] Example 5: Includes other […] 225 Protective effects of Ac-labeled compounds in various formulations
[0287] In this study, different pathways targeting PSMA (PSMA-I&T, PSMA-617), integrin (DOTA-RGD), or somatostatin receptor (JR11, DOTATOC) were tested. 225 Various formulations of Ac-labeled conjugates regarding this... 225 The protective effect of Ac-labeled conjugates on radiochemical stability over a period of up to 72 hours.
[0288] For this purpose, radiolabeling of the different conjugates was performed as described in Example 1 (radiolabeling according to #1.7), except that the precursor of each conjugate (DOTA conjugate 9) was used instead of the DOTA-PSMA precursor (DOTA-Ibu-DAB-PSMA) used in Example 1. The radiolabeled conjugates were diluted in reaction vials with formulation buffer, transferred to product vials by sterile filtration, and shelf life was determined in stability studies by periodic analysis at 72 hours.
[0289] The tested formulations and results are shown in Table 5 below.
[0290] Table 5: Different radiolabeling methods according to #1.7 225Stability Study of Ac]Ac-labeled Conjugates
[0291]
[0292] M: Molar concentration (mol / L); NaOAc: Sodium acetate; EtOH: Ethanol; Ac: Actinium-225; EOS: End of synthesis; RAC: Radioactive concentration; ART: Activity reference time; RCP: Radiochemical purity; nd: Not determined.
[0293] The results shown in Table 5 demonstrate that, even with different radioactive concentrations, the formulations containing NaOAc, ethanol, and sodium ascorbate still exhibited strong protection against radiodegradation 72 hours after synthesis. Specifically, all tested formulations achieved >95% radiochemical purity at 72 hours. For all tested formulations, the content of free (uncomplexed) Ac at the end of synthesis was ≤0.5%, and the content of free (uncomplexed) Ac in the final composition remained low (≤1.4%) after 72 hours.
[0294] The radiolabeling and preparation method of the present invention ensures a radiochemical yield ≥99%, and within a defined concentration range, after […]. 225 Ac]Ac-labeled conjugates (targeting moieties covalently linked to the chelate moiety) exhibit radiodecomposition stability with a radiochemical purity ≥94% within 72 hours. This leads to [ 225 Ac-labeled radiopharmaceuticals offer high purity and prolonged stability. Their extended stability (72 hours) and consistent high quality allow for centralized production and subsequent distribution to treatment centers. Furthermore, there is no need to purify the labeled final product or add weak chelating agents to the formulation.
Claims
1. A pharmaceutical composition comprising... (a) A radiolabeled complex containing (i) 225 Ac(actinium-225) radionuclide, and (ii) a targeting portion that targets prostate-specific membrane antigen (PSMA) or αvβ3 integrin, said targeting portion being covalently linked to the chelating portion; and (b) Stabilizers that resist radiation degradation. The stabilizer mentioned above contains sodium acetate (NaOAc) and ethanol (EtOH).
2. The pharmaceutical composition according to claim 1, wherein the concentration of sodium acetate in the composition is 9 mg / mL to 100 mg / mL, preferably 15 mg / mL to 100 mg / mL, more preferably 20 mg / mL to 90 mg / mL, more preferably 30 mg / mL to 80 mg / mL, even more preferably 40 mg / mL to 70 mg / mL, and even more preferably 50 mg / mL to 60 mg / mL, or wherein the concentration of sodium acetate in the composition is 7 mg / mL to 20 mg / mL, preferably 7 mg / mL to 15 mg / mL, more preferably 9 mg / mL to 15 mg / mL, or most preferably 7 mg / mL to 12 mg / mL.
3. The pharmaceutical composition according to any one of the preceding claims, wherein the concentration of ethanol in the composition is from 1% (vol / vol) to 30% (vol / vol), preferably from 2% (vol / vol) to 20% (vol / vol), more preferably from 2 vol.% to 7 vol.%, even more preferably from 3 vol.% to 5 vol.%, and most preferably from 3.5 vol.% to 4.5 vol.%.
4. The pharmaceutical composition according to any one of the preceding claims, wherein the composition is an aqueous solution.
5. The pharmaceutical composition according to any one of the preceding claims, wherein the stabilizer further comprises ascorbic acid and / or its salt.
6. The pharmaceutical composition according to claim 5, wherein the salt of ascorbic acid is sodium ascorbate.
7. The pharmaceutical composition according to any one of the preceding claims, wherein the concentration of ascorbic acid salt, particularly sodium ascorbate, in the composition is less than 40 mg / mL, preferably 20 mg / mL to 40 mg / mL, more preferably 30 mg / mL to 40 mg / mL.
8. The pharmaceutical composition according to any one of the preceding claims, wherein the excipients of the pharmaceutical composition are substantially composed of sodium acetate, ethanol, optionally sodium ascorbate and water.
9. The pharmaceutical composition according to any one of the preceding claims, wherein the composition comprises 9.0 mg / mL to 100 mg / mL of NaOAc, 2 vol.% to 20 vol.% of ethanol and 0 mg / mL to 40 mg / mL of Na-ascorbate.
10. The pharmaceutical composition according to any one of the preceding claims, wherein (i) the composition comprises 7 mg / mL to 12 mg / mL of NaOAc, 3 vol.% to 5 vol.% of ethanol and 30 mg / mL to 40 mg / mL of Na-ascorbate, (ii) the composition does not contain a chelating agent, and (iii) the composition does not contain any one of gentianic acid or a salt thereof, methionine, histidine, melatonin and Se-methionine.
11. The pharmaceutical composition according to any one of the preceding claims, wherein the concentration of the targeting portion connected to the chelating portion in the composition is from 10 nmol / mL to 150 nmol / mL, preferably from 10 nmol / mL to 130 nmol / mL.
12. The pharmaceutical composition according to any one of the preceding claims, wherein the concentration of the targeting portion connected to the chelating portion in the composition is from 20 µg / mL to 200 µg / mL, particularly from 30 µg / mL to 160 µg / mL.
13. The pharmaceutical composition according to any one of the preceding claims, wherein the chelating portion is DOTA or a derivative thereof.
14. The pharmaceutical composition according to any one of the preceding claims, wherein the targeting portion is selected from peptides, peptide mimics, antibodies, antibody fragments, and antibody mimics.
15. The pharmaceutical composition according to any one of the preceding claims, wherein the radiolabeled complex comprises or constitutes (i) 225 Ac (actinium-225) radionuclide and (ii) DOTA-linked peptide or DOTA derivative-linked peptide, wherein the DOTA-linked peptide or DOTA derivative-linked peptide is selected from PSMA-617, PSMA-I&T, Ibu-DAB-PSMA and DOTA-RGD.
16. The pharmaceutical composition according to any one of the preceding claims, wherein the radiolabeled complex comprises or constitutes (i) 225 Ac(actinium-225) radionuclides and (ii)Ibu-DAB-PSMA, more preferably (S)-Ibu-DAB-PSMA.
17. The pharmaceutical composition according to any one of the preceding claims, wherein... 225 Ac radionuclides are present at concentrations providing volumetric radioactivity of 0.4 MBq / mL to 4.0 MBq / mL, preferably 1 MBq / mL to 4.0 MBq / mL, or wherein... 225 Ac radionuclides are present at a concentration providing volumetric radioactivity of 0.2 MBq / mL to 2.0 MBq / mL, preferably 0.2 MBq / mL to 1.0 MBq / mL, more preferably 0.3 MBq / mL to 0.8 MBq / mL, and most preferably 0.35 MBq / mL to 0.45 MBq / mL.
18. The pharmaceutical composition according to any one of the preceding claims, wherein (i) the composition comprises 7 mg / mL to 12 mg / mL of NaOAc, 3 vol.% to 5 vol.% of ethanol and 30 mg / mL to 40 mg / mL of Na-ascorbate, (ii) the composition does not contain a chelating agent, (iii) the composition does not contain any one of gentianic acid or a salt thereof, methionine, histidine, melatonin and Se-methionine, and (iv) wherein 225 Ac radionuclides exist at concentrations providing volumetric radioactivity of 0.3 MBq / mL to 0.8 MBq / mL, preferably 0.35 MBq / mL to 0.45 MBq / mL.
19. The pharmaceutical composition according to any one of the preceding claims, wherein (i) the composition comprises 7 mg / mL to 12 mg / mL of NaOAc, 3 vol.% to 5 vol.% of ethanol and 30 mg / mL to 40 mg / mL of Na-ascorbate, (ii) the composition does not contain a chelating agent, (iii) the composition does not contain any one of gentianic acid or a salt thereof, methionine, histidine, melatonin and Se-methionine, (iv) wherein 225 The Ac radionuclide is present at a concentration providing volumetric radioactivity of 0.3 MBq / mL to 0.8 MBq / mL, preferably 0.35 MBq / mL to 0.45 MBq / mL, and (v) wherein the radiolabeled complex comprises or constitutes the following: 225 Ac(actinium-225) radionuclides and Ibu-DAB-PSMA, more preferably (S)-Ibu-DAB-PSMA.
20. The pharmaceutical composition according to any one of the preceding claims, wherein the composition has a shelf life of at least 72 hours.
21. The pharmaceutical composition according to any one of the preceding claims, wherein the radiochemical purity of the composition is maintained at ≥94% for at least 72 hours.
22. The pharmaceutical composition according to any one of the preceding claims, wherein the composition is provided in a volume of 1 mL to 10 mL.
23. The pharmaceutical composition according to any one of the preceding claims, wherein a single dose allows delivery of 0.5 MBq ± 10% to 40 MBq ± 10% radioactivity at injection, preferably 1 MBq ± 10% to 20 MBq ± 10% radioactivity at injection, more preferably about 2 MBq ± 10% to 12 MBq ± 10% radioactivity at injection.
24. A pharmaceutical composition according to any one of the preceding claims, used in medicine.
25. A pharmaceutical composition according to any one of the preceding claims, for treating cancer.
26. A method for treating cancer or inducing, enhancing or prolonging an antitumor response in a subject in need, comprising administering to said subject a pharmaceutical composition according to any one of claims 1 to 25.
27. A method for radiolabeling a target portion covalently linked to a chelate moiety using 225-actinium, comprising the following steps: (a) will 225 Ac radionuclide, a radiolabeled precursor containing a target portion covalently linked to the chelating portion, and a radiolabeled buffer containing sodium acetate and ethanol are combined. and (b) Heating the mixture for a predetermined period of time to obtain the desired effect. 225 Ac-labeled complexes, the via 225 Ac-labeled complexes contain 225 Ac radionuclides and the target portion covalently linked to the chelating portion.
28. A method for preparing a pharmaceutical composition, comprising the following steps: (a') A radiolabeled complex (radiolabel) is formed by heating a radiolabeled solution for a defined time period, the radiolabeled solution comprising (i) 225 Ac (actinium-225) radionuclide, (ii) a radiolabeled precursor containing a target moiety covalently linked to the chelate moiety, and (iii) a radiolabeled buffer containing sodium acetate (NaOAc) and ethanol. (b') The pharmaceutical composition is formulated by adding a formulation buffer containing water, particularly water for injection, sodium acetate and ethanol, and optionally a salt of ascorbic acid, particularly Na-ascorbate; and (c') optionally apply the obtained experience 225 The solution of the Ac-labeled complex was sterilized and filtered.
29. The method according to claim 27 or 28, wherein sodium acetate is present at a concentration of 9 mg / mL to 100 mg / mL, preferably 10 mg / mL to 100 mg / mL, more preferably 20 mg / mL to 90 mg / mL, more preferably 30 mg / mL to 80 mg / mL, even more preferably 40 mg / mL to 70 mg / mL, and still more preferably 50 mg / mL to 60 mg / mL during step (a) and / or step (a').
30. The method according to any one of claims 27 to 29, wherein ethanol is present at a concentration of 1% (vol / vol) to 30% (vol / vol), preferably 2% (vol / vol) to 20% (vol / vol), respectively, during step (a) and / or step (a').
31. The method according to any one of claims 27 to 30, wherein the formation of the radiolabeled complex (radiolabel) is carried out in an aqueous solution.
32. The method according to any one of claims 27 to 31, wherein the radiolabeled buffer does not contain ascorbic acid or a salt thereof, preferably not sodium ascorbate, and / or does not contain gentianic acid or a salt thereof.
33. The method according to any one of claims 27 to 32, wherein the radiolabeled buffer solution is substantially composed of sodium acetate, ethanol and water.
34. The method according to any one of claims 27 to 33, wherein in step (a) and step (a') respectively, 225 The actinide radionuclide is present in the radiolabeled composition at a concentration providing volumetric radioactivity of 0.4 MBq / mL to 4.0 MBq / mL, preferably 1 MBq / mL to 4 MBq / mL, or 0.2 MBq / mL to 2.0 MBq / mL, preferably 0.2 MBq / mL to 1.0 MBq / mL.
35. The method according to any one of claims 27 to 34, wherein the targeting portion connected to the chelating portion is present in the radiolabeled composition at a concentration of 10 nmol / mL to 150 nmol / mL, preferably 10 nmol / mL to 130 nmol / mL.
36. The method according to any one of claims 27 to 35, wherein the radiolabeled buffer solution has a pH of about 6.0 to 9.0, preferably about 7 to 8, more preferably about 7.
0.
37. The method according to any one of claims 27 to 36, wherein the radioactive labeling of the precursor is performed at a temperature of 80°C to 95°C, preferably 85°C to 90°C, more preferably about 87°C.
38. The method according to any one of claims 27 to 37, wherein the radiolabeling of the precursor is performed for 5 to 30 minutes, preferably 8 to 25 minutes.
39. The method according to any one of claims 28 to 38, wherein the formulation buffer added in step (b') comprises a salt of ascorbic acid, particularly sodium ascorbate.
40. The method according to any one of claims 28 to 39, wherein the formulation buffer added in step (b') consists essentially of water, particularly water for injection, sodium acetate, ethanol and sodium ascorbate.
41. The method according to claim 39 or 40, wherein the formulation buffer containing sodium ascorbate is added in an amount such that the concentration of sodium ascorbate in the composition is less than 40 mg / mL, preferably from 20 mg / mL to 40 mg / mL, more preferably from 30 mg / mL to 40 mg / mL.
42. The method according to any one of claims 27 to 41, wherein the targeting portion is selected from peptides, peptide mimics, antibodies, antibody fragments, and antibody mimics.
43. The method according to any one of claims 27 to 42, wherein the targeting portion targets prostate-specific membrane antigen (PSMA), integrin, or somatostatin receptor.
44. The method according to any one of claims 27 to 43, wherein the chelating portion is DOTA or a derivative thereof.
45. The method according to any one of claims 27 to 44, wherein the radiolabeled complex comprises or consists of (i) 225 Ac (actinium-225) radionuclide and (ii) DOTA-linked peptide or DOTA derivative-linked peptide, wherein the DOTA-linked peptide or DOTA derivative-linked peptide is selected from PSMA-I&T, PSMA-617, Ibu-DAB-PSMA, DOTA-RGD, DOTA-JR11, DOTATOC and DOTATATE.
46. The method according to any one of claims 28 to 45, wherein the method is used to prepare a pharmaceutical composition according to any one of claims 1 to 25.
47. A pharmaceutical composition obtained by the method according to any one of claims 27 to 46.
48. The pharmaceutical composition of claim 47, wherein the pharmaceutical composition is defined as in any one of claims 1 to 25.
Citation Information
Patent Citations
Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP2862857A1
In situ thermal control of langmuir-schaefer transfer
US10756278B2
Stabilized compositions of radionuclides and uses thereof
US20230144360A1
Radiolabeled prostate specific membrane antigen inhibitors
WO2013022797A1
Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2015055318A1
